1
|
Probst-Hensch N, Imboden M, Jeong A, Keidel D, Vermes T, Witzig M, Cullati S, Tancredi S, Noor N, Rodondi PY, Harju E, Michel G, Frank I, Kahlert C, Cusini A, Rodondi N, Chocano-Bedoya PO, Bardoczi JB, Stuber MJ, Vollrath F, Fehr J, Frei A, Kaufmann M, Geigges M, von Wyl V, Puhan MA, Albanese E, Crivelli L, Lovison GF. Long-term trajectories of densely reported depressive symptoms during an extended period of the COVID-19 pandemic in Switzerland: Social worries matter. Compr Psychiatry 2024; 130:152457. [PMID: 38325041 DOI: 10.1016/j.comppsych.2024.152457] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/06/2023] [Revised: 01/04/2024] [Accepted: 01/29/2024] [Indexed: 02/09/2024] Open
Abstract
Previous mental health trajectory studies were mostly limited to the months before access to vaccination. They are not informing on whether public mental health has adapted to the pandemic. The aim of this analysis was to 1) investigate trajectories of monthly reported depressive symptoms from July 2020 to December 2021 in Switzerland, 2) compare average growth trajectories across regions with different stringency phases, and 3) explore the relative impact of self-reported worries related to health, economic and social domains as well as socio-economic indicators on growth trajectories. As part of the population-based Corona Immunitas program of regional, but harmonized, adult cohorts studying the pandemic course and impact, participants repeatedly reported online to the DASS-21 instrument on depressive symptomatology. Trajectories of depressive symptoms were estimated using a latent growth model, specified as a generalised linear mixed model. The time effect was modelled parametrically through a polynomial allowing to estimate trajectories for participants' missing time points. In all regions level and shape of the trajectories mirrored those of the KOF Stringency-Plus Index, which quantifies regional Covid-19 policy stringency. The higher level of average depression in trajectories of those expressing specific worries was most noticeable for the social domain. Younger age, female gender, and low household income went along with higher mean depression score trajectories throughout follow-up. Interventions to promote long-term resilience are an important part of pandemic preparedness, given the observed lack of an adaptation in mental health response to the pandemic even after the availability of vaccines in this high-income context.
Collapse
Affiliation(s)
- N Probst-Hensch
- Swiss Tropical and Public Health Institute, Allschwil, Switzerland; Department of Public Health, University of Basel, Switzerland.
| | - M Imboden
- Swiss Tropical and Public Health Institute, Allschwil, Switzerland; Department of Public Health, University of Basel, Switzerland
| | - A Jeong
- Swiss Tropical and Public Health Institute, Allschwil, Switzerland; Department of Public Health, University of Basel, Switzerland
| | - D Keidel
- Swiss Tropical and Public Health Institute, Allschwil, Switzerland; Department of Public Health, University of Basel, Switzerland
| | - T Vermes
- Swiss Tropical and Public Health Institute, Allschwil, Switzerland; Department of Public Health, University of Basel, Switzerland
| | - M Witzig
- Swiss Tropical and Public Health Institute, Allschwil, Switzerland; Department of Public Health, University of Basel, Switzerland
| | - S Cullati
- Population Health Laboratory (#PopHealthLab), University of Fribourg, Fribourg, Switzerland; Department of Readaptation and Geriatrics, University of Geneva, Geneva, Switzerland
| | - S Tancredi
- Population Health Laboratory (#PopHealthLab), University of Fribourg, Fribourg, Switzerland
| | - N Noor
- Population Health Laboratory (#PopHealthLab), University of Fribourg, Fribourg, Switzerland
| | - P-Y Rodondi
- Institute of Family Medicine (IMF), University of Fribourg, Fribourg, Switzerland
| | - E Harju
- Faculty of Health Sciences and Medicine, University of Lucerne, Alpenquai 4, 6005 Luzern, Switzerland.; ZHAW Zurich University of Applied Sciences, School of Health Sciences, Winterthur, Switzerland
| | - G Michel
- Faculty of Health Sciences and Medicine, University of Lucerne, Alpenquai 4, 6005 Luzern, Switzerland
| | - I Frank
- Clinical Trial Unit, Cantonal Hospital Luzern, Luzern, Switzerland
| | - C Kahlert
- Department of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland; Infectious Diseases and Hospital Epidemiology, Children's Hospital of Eastern Switzerland, St. Gallen, Switzerland
| | - A Cusini
- Division of Infectious Diseases, Cantonal Hospital of Grisons, Chur, Switzerland
| | - N Rodondi
- Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland; Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | - P O Chocano-Bedoya
- Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland
| | - J B Bardoczi
- Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland; Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | - M J Stuber
- Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland; Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | - F Vollrath
- Corona Immunitas Program Management Group, Swiss School of Public Health, Zurich, Switzerland
| | - J Fehr
- Epidemiology, Biostatistics and Prevention Institute, Zurich, Switzerland
| | - A Frei
- Epidemiology, Biostatistics and Prevention Institute, Zurich, Switzerland
| | - M Kaufmann
- Epidemiology, Biostatistics and Prevention Institute, Zurich, Switzerland
| | - M Geigges
- Epidemiology, Biostatistics and Prevention Institute, Zurich, Switzerland
| | - V von Wyl
- Institute for Implementation Science in Health Care, University of Zurich, Zurich, Switzerland
| | - M A Puhan
- Epidemiology, Biostatistics and Prevention Institute, Zurich, Switzerland
| | - E Albanese
- Institute of Public Health, Faculty of BioMedicine, Università Della Svizzera Italiana, Lugano, Switzerland
| | - L Crivelli
- Institute of Public Health, Faculty of BioMedicine, Università Della Svizzera Italiana, Lugano, Switzerland; Department of Business Economics, Health and Social Care, University of Applied Sciences and Arts of Southern Switzerland, Lugano, Switzerland
| | - G F Lovison
- Swiss Tropical and Public Health Institute, Allschwil, Switzerland; Department of Public Health, University of Basel, Switzerland
| |
Collapse
|
2
|
Legendre M, Morin J, Cuadrado J, Côté M, Michel G, Bégin C. Muscle dysmorphia from an addictive perspective: Validation of the Addiction to Body Image Inventory (ABII). Encephale 2024; 50:20-25. [PMID: 36528392 DOI: 10.1016/j.encep.2022.10.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/01/2022] [Revised: 10/11/2022] [Accepted: 10/15/2022] [Indexed: 12/23/2022]
Abstract
OBJECTIVES Muscle dysmorphia (MD) is a disorder affecting mainly men and is characterized by significant dissatisfaction with muscles. The idea that MD could represent an addiction has been theoretically discussed, but no empirical data are available. Based on Foster et al. (2015) framework, the Addiction to Body Image Inventory (ABII) was developed. This study aims to validate the ABII and to evaluate its capacity to capture MD severity. METHODS A first community sample of 466 participants was recruited and completed the ABII and questionnaires on MD and body esteem. A second sample of 47 men at risk of MD was recruited mostly in gyms and completed the ABII and questionnaires on MD, eating and psychological symptoms. RESULTS With the community sample, the results showed that the ABII had a valid factorial structure, good internal consistency, and good convergent validity. With the sample of men at risk of MD, the results showed that the ABII had good convergent validity with MD and eating symptoms but not with psychological symptoms. The results of a regression model showed that the ABII explained 12% of the MD variance. CONCLUSIONS This study brings the first measure of addiction to body image and suggests that MD must be understood as a complex phenomenon including eating symptoms and addictive tendencies.
Collapse
Affiliation(s)
- M Legendre
- School of Psychology, Pavillon Félix-Antoine-Savard, Laval University, 2325, rue des Bibliothèques, Quebec (QC), G1V 0A6, Canada
| | - J Morin
- School of Psychology, Pavillon Félix-Antoine-Savard, Laval University, 2325, rue des Bibliothèques, Quebec (QC), G1V 0A6, Canada
| | - J Cuadrado
- Équipe Healthy, Inserm U1219, Bordeaux Population Health Research Center, Université de Bordeaux, 3ter, place de la victoire, 33000 Bordeaux, France
| | - M Côté
- School of Psychology, Pavillon Félix-Antoine-Savard, Laval University, 2325, rue des Bibliothèques, Quebec (QC), G1V 0A6, Canada
| | - G Michel
- Équipe Healthy, Inserm U1219, Bordeaux Population Health Research Center, Université de Bordeaux, 3ter, place de la victoire, 33000 Bordeaux, France
| | - C Bégin
- School of Psychology, Pavillon Félix-Antoine-Savard, Laval University, 2325, rue des Bibliothèques, Quebec (QC), G1V 0A6, Canada. %20
| |
Collapse
|
3
|
Giorgiutti S, Ballonzoli L, Michel G, Eischen A, Toussaint E, Nicolae A, Gaucher D, Poindron V. Masquerade syndrome: Retinal biopsy to diagnose primary intraocular lymphoma. J Fr Ophtalmol 2023; 46:996-997. [PMID: 37085372 DOI: 10.1016/j.jfo.2023.01.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2023] [Accepted: 01/19/2023] [Indexed: 04/23/2023]
Affiliation(s)
- S Giorgiutti
- Service d'immunologie clinique et médecine interne, centre de références des maladies auto-immunes et systémiques rares (CNR RESO), hôpitaux universitaires de Strasbourg, 1, place de l'hôpital, 67091 Strasbourg, France.
| | - L Ballonzoli
- Service d'ophtalmologie, hôpitaux universitaires de Strasbourg, 1, place de l'hôpital, 67091 Strasbourg, France
| | - G Michel
- Cabinet d'ophthalmologie, 6, rue de l'église, 67000 Strasbourg, France
| | - A Eischen
- Laboratoire d'hématologie, hôpitaux universitaires de Strasbourg, 1, place de l'hôpital, 67091 Strasbourg, France
| | - E Toussaint
- Service d'hématologie, institut de cancérologie Strasbourg Europe, 17, rue Albert-Calmette, 67200 Strasbourg, France
| | - A Nicolae
- Laboratoire de pathologie, hôpitaux universitaires de Strasbourg, 1, place de l'hôpital, 67091 Strasbourg, France
| | - D Gaucher
- Service d'ophtalmologie, hôpitaux universitaires de Strasbourg, 1, place de l'hôpital, 67091 Strasbourg, France
| | - V Poindron
- Service d'immunologie clinique et médecine interne, centre de références des maladies auto-immunes et systémiques rares (CNR RESO), hôpitaux universitaires de Strasbourg, 1, place de l'hôpital, 67091 Strasbourg, France
| |
Collapse
|
4
|
Boumghit Y, Boucher S, Godey B, Michel G, Bakhos D. Speech reception after cochlear implantation for Cogan's syndrome: Case series following CARE guidelines. Eur Ann Otorhinolaryngol Head Neck Dis 2023; 140:235-238. [PMID: 37479606 DOI: 10.1016/j.anorl.2023.06.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/23/2023]
Abstract
INTRODUCTION Cogan's syndrome is a rare form of vasculitis mainly affecting young subjects of whatever gender, associating cochleovestibular and ophthalmological damage. Despite medical treatment, auditory prognosis is uncertain, with 50-60% of patients showing irreversible severe to profound hearing loss, thus being candidates for cochlear implantation. Following CARE guidelines, we report 10 cases of cochlear implantation in Cogan's syndrome, with assessment of speech reception threshold and maximum intelligibility after a minimum 1 year's experience with the implant. CASE SERIES Ten patients from 4 centers received cochlear implants (14 implants) for Cogan's syndrome between 2005 and 2020. After 1 year's experience, there was significant improvement in speech reception threshold (P=0.0002) and maximum intelligibility (P=0.0002). CONCLUSION-DISCUSSION Audiovestibular signs associated with ophthalmological manifestations should suggest Cogan's syndrome. Hearing impairment is usually irreversible. Cochlear implantation may be necessary and improves hearing performance.
Collapse
Affiliation(s)
- Y Boumghit
- Service ORL et chirurgie cervico-faciale, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours, France.
| | - S Boucher
- Service ORL et chirurgie cervico-faciale, CHU d'Angers, 4, rue Larrey, 49000 Angers, France
| | - B Godey
- Service ORL et chirurgie cervico-faciale, CHU de Rennes, 2, rue Henri-le-Guilloux, 35000 Rennes, France
| | - G Michel
- Service ORL et chirurgie cervico-faciale, CHU de Nantes, 1, place Alexis-Ricordeau, 44093 Nantes, France
| | - D Bakhos
- Service ORL et chirurgie cervico-faciale, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours, France; Inserm U1253, iBrain, université de Tours, 10, boulevard Tonnellé, 37000 Tours, France; House Institute Foundation, Los Angeles, United States
| |
Collapse
|
5
|
Normant S, Gendre A, Boucher S, Godey B, Bordure P, Michel G. Predictive factors of revision stapes surgery in otosclerosis. J Laryngol Otol 2023; 137:906-909. [PMID: 36511130 DOI: 10.1017/s0022215122002572] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
OBJECTIVES This study aimed to investigate predictive factors for revision surgery in otosclerosis. METHODS This was a retrospective, multicentre study in four tertiary centres. The primary objective was to investigate factors that were predictive of the need for revision stapes surgery. RESULTS The 'revision' group included 145 patients, and the 'control' group included 143 patients. This study identified statistically significant predictive factors for the need for revision surgery: younger age, active smoking status, dyslipidaemia and high blood pressure. There was no statistically significant difference between the two groups in terms of surgical technique or stapedotomy technique. CONCLUSION This study showed that patients who are candidates for primary stapes surgery with younger age, active smoking status, dyslipidaemia and high blood pressure are at higher risk of needing revision surgery. A holistic approach prior to stapes surgery with multidisciplinary assessment is recommended. These results are important for better patient counselling on expected outcomes and risks.
Collapse
Affiliation(s)
- S Normant
- Department of Otorhinolaryngology, University Hospital of Nantes, France
| | - A Gendre
- Department of Otorhinolaryngology, University Hospital of Nantes, France
| | - S Boucher
- Department of Otorhinolaryngology, University Hospital of Angers, France
| | - B Godey
- Department of Otorhinolaryngology, University Hospital of Rennes, France
| | - P Bordure
- Department of Otorhinolaryngology, University Hospital of Nantes, France
| | - G Michel
- Department of Otorhinolaryngology, University Hospital of Nantes, France
| |
Collapse
|
6
|
Vergier J, Reynaud R, Michel G, Auquier P, Courbiere B. Misconceptions and beliefs around hormone replacement therapy after childhood hematopoietic stem cell transplantation: A qualitative study among women leukemia survivors. PLoS One 2023; 18:e0283940. [PMID: 37040357 PMCID: PMC10089326 DOI: 10.1371/journal.pone.0283940] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2022] [Accepted: 03/21/2023] [Indexed: 04/12/2023] Open
Abstract
PURPOSE After childhood leukemia and hematopoietic stem cell transplantation, hormone replacement therapy is often required to induce puberty because of premature ovarian insufficiency. Observance of this kind of treatment in adolescents and young women seems quite poor, and literature about its acceptance remains scarce; in order to learn about their experience and to better understand their attitude towards hormone replacement therapy, we used qualitative methods. DESIGN AND PATIENTS 13 young women childhood cancer survivors completed an individual interview. RESULTS We report that the negative experience of leukemia may cause rejection of the treatment, closely related to infertility unacceptance. Misconceptions and lack of adequate information of hormonal treatment effects are also major barriers to a good compliance. CONCLUSIONS AND IMPLICATIONS FOR CANCER SURVIVORS Observance of hormone replacement therapy for young women childhood cancer survivors can be improved with a confidential patient-physician relationship, patient education, choice of galenic formulation according to personal preference, and psychological support during the long-time follow up.
Collapse
Affiliation(s)
- Julia Vergier
- Department of Paediatrics, Paediatric Endocrinology Unit, CHU Timone Enfants, Assistance Publique-Hôpitaux de Marseille (APHM), Marseille, France
| | - Rachel Reynaud
- Department of Paediatrics, Paediatric Endocrinology Unit, CHU Timone Enfants, Assistance Publique-Hôpitaux de Marseille (APHM), Marseille, France
- Aix-Marseille Univ, Institut National de la Santé et de la Recherche Médicale (INSERM), U1251, Marseille Medical Genetics (MMG), Marseille, France
| | - Gerard Michel
- Department of Pediatric Hematology and Oncology, CHU Timone Enfants, Assistance Publique-Hôpitaux de Marseille (APHM), Marseille, France
- Aix-Marseille Univ, Research Unit Equipe d'Accueil 3279, Marseille, France
| | - Pascal Auquier
- Aix-Marseille Univ, EA 3279: CEReSS-Health Service Research and Quality of Life Center, Marseille, France
| | - Blandine Courbiere
- Aix Marseille Univ, Avignon Univ, CNRS, IRD, IBME, Marseille, France
- Assistance-Publique des Hôpitaux de Marseille (APHM), Pôle Femmes-Parents-Enfants, Centre Clinico-Biologique AMP-CECOS, Plateforme Cancer et Fertilité ONCOPACA-Corse, Marseille, France
| |
Collapse
|
7
|
Garcia M, Rouchy E, Michel G. Temperament and character profiles of adolescent participants in the choking game. Arch Pediatr 2022; 29:475-479. [PMID: 36109289 DOI: 10.1016/j.arcped.2022.06.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2021] [Revised: 04/25/2022] [Accepted: 06/18/2022] [Indexed: 11/17/2022]
Abstract
OBJECTIVE The role of personality traits in self-asphyxial behaviors remains largely unexplored. The aim of this study was to explore temperament and character profiles of youth reporting participation in the choking game using Cloninger's biopsychosocial model of personality. METHODS Data were collected among French middle-school students (N=1771) aged 9-16 years (mean age=13.0, SD=1.3) and randomly selected from 13 public establishments located in different regions of France. Logistic regression models were run to identify Cloninger's temperamental and character dimensions associated with engagement in the choking game. RESULTS Descriptive analysis revealed that participants showed high scores of novelty-seeking (Cohen's d=0.293, p<0.001) and low levels of cooperativeness (Cohen's d=0.182, p<0.01), persistence (Cohen's d=0.182, p<0.05), and reward dependence (Cohen's d=0.241, p<0.01). However, multivariate modeling indicated that only the novelty-seeking dimension tended to slightly differentiate participants from non-participants within the global sample (OR=1.03, 95% CI: 1-1.06). When we compared girls and boys, we found a slight trend in association only in boys (OR=1.04, 95% CI: 1-1.08). CONCLUSIONS Our study, which contributes to the growing literature on the psychological correlates of choking activities and is the first to investigate the potential predictive role of personality traits in this risky behavior, suggests to some extent that (a) the choking game could possibly be influenced by some temperamental characteristics, and that (b) it might not have the same function according to the gender considered.
Collapse
Affiliation(s)
- M Garcia
- Institut de Sciences Criminelles et de la Justice (ISCJ), University of Bordeaux, France; Department of Psychology, University of Bordeaux, France.
| | - E Rouchy
- Institut de Sciences Criminelles et de la Justice (ISCJ), University of Bordeaux, France; Department of Psychology, University of Bordeaux, France
| | - G Michel
- Institut de Sciences Criminelles et de la Justice (ISCJ), University of Bordeaux, France; Department of Psychology, University of Bordeaux, France
| |
Collapse
|
8
|
Gebauer J, Skinner R, Haupt R, Kremer L, van der Pal H, Michel G, Armstrong GT, Hudson MM, Hjorth L, Lehnert H, Langer T. The chance of transition: strategies for multidisciplinary collaboration. Endocr Connect 2022; 11:e220083. [PMID: 35900792 PMCID: PMC9422248 DOI: 10.1530/ec-22-0083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/14/2022] [Accepted: 07/13/2022] [Indexed: 11/08/2022]
Abstract
Many long-term childhood cancer survivors suffer from treatment-related late effects, which may occur in any organ and include a wide spectrum of conditions. Long-term follow-up (LTFU) is recommended to facilitate early diagnosis and to ensure better health outcomes. Due to the heterogeneity of these sequelae, different specialists work together in the diagnosis and treatment of these conditions. Experts from both pediatric and internal medicine are involved in age-appropriate care by providing a transition process. Hence, LTFU of childhood cancer survivors is a prototypic example of multidisciplinary care for patients with complex needs treated in a specialized setting. International collaborations of healthcare professionals and scientists involved in LTFU of childhood cancer survivors, such as the International Guideline Harmonization Group, compile surveillance recommendations that can be clinically adopted all over the world. These global networks of clinicians and researchers make a joint effort to address gaps in knowledge, increase visibility and awareness of cancer survivorship and provide an excellent example of how progress in clinical care and scientific research may be achieved by international and multidisciplinary collaboration.
Collapse
Affiliation(s)
- J Gebauer
- Department of Internal Medicine I, University Hospital of Schleswig-Holstein, Campus Luebeck and Institute for Endocrinology and Diabetes, University of Luebeck, Luebeck, Germany
| | - R Skinner
- Department of Paediatric and Adolescent Haematology and Oncology and Children’s BMT Unit, Great North Children’s Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, and Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK
| | - R Haupt
- DOPO Clinic, Department of Hematology/Oncolgy, IRCCS Istituto Giannina Gaslini, Genova, Italy
| | - L Kremer
- Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
- Amsterdam UMC, Emma’s Children’s Hospital, Amsterdam, The Netherlands
| | - H van der Pal
- Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
| | - G Michel
- Department of Health Sciences and Medicine, University of Lucerne, Luzern, Switzerland
| | - G T Armstrong
- Department of Epidemiology and Cancer Control, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
| | - M M Hudson
- Department of Oncology, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
| | - L Hjorth
- Department of Clinical Sciences Lund, Paediatrics, Lund University, Skane University Hospital, Lund, Sweden
| | - H Lehnert
- Paris Lodron University of Salzburg, Salzburg, Austria
| | - T Langer
- Pediatric Hematology and Oncology, University Hospital of Schleswig-Holstein, Campus Luebeck, Luebeck, Germany
| |
Collapse
|
9
|
Rialland F, Grain A, Labopin M, Michel G, Gandemer V, Paillard C, Pochon C, Clement L, Brissot E, Jubert C, Sirvent A, Rohrlich PS, Plantaz D, Dalle JH, Mohty M. Reduced-toxicity myeloablative conditioning regimen using fludarabine and full doses of intravenous busulfan in pediatric patients not eligible for standard myeloablative conditioning regimens: Results of a multicenter prospective phase 2 trial. Bone Marrow Transplant 2022; 57:1698-1703. [PMID: 36028757 DOI: 10.1038/s41409-022-01769-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2022] [Revised: 07/18/2022] [Accepted: 07/21/2022] [Indexed: 11/09/2022]
Abstract
Data regarding the safety and efficacy of reduced-toxicity conditioning regimen (RTC) prior to allogeneic stem cell transplantation (allo-SCT) to treat hematological malignancies in pediatric patients are limited. This prospective multicenter, phase 2 trial investigated a RTC regimen based on the combination of intravenous busulfan (3.2 mg/kg/d x 4 days), fludarabine (30 mg/m2/d x 5 days) and antithymocyte globulin (Thymoglobulin®, Genzyme; 5 mg/kg total dose) with the aim of delivering high dose myeloablation that would allow optimal disease control while minimizing toxicity, in a subgroup of children at very high risk of non-relapse mortality (NRM). The primary endpoint was NRM at 1 year after allo-SCT. A total of 48 high risk patients were included (median age, 13 years; range, 3-24). At 1 year, the cumulative incidence of recurrence/disease progression and NRM were 33% and 8%, respectively. With a median follow-up of 23 months, the Kaplan-Meier estimates of overall survival (OS) and disease-free survival (DFS) at 1 year were 69% and 58%, respectively. We conclude that the RTC regimen used in this prospective trial is safe, with a < 10% NRM rate noted among high-risk children and adolescents, paving the way for larger phase 3 trials incorporating novel agents pre- and post-allo-SCT.(ClinicalTrials.gov Identifier: NCT01572181).
Collapse
Affiliation(s)
| | | | - Myriam Labopin
- Sorbonne University, Saint-Antoine Hospital, AP-HP, INSERM UMRs 938, Paris, France
| | - Gerard Michel
- Department of Pediatric Immunology, Hematology and Oncology, Timone Enfants Hospital and Aix-Marseille University, Marseille, France
| | - Virginie Gandemer
- University hospital of Rennes, University of Rennes1, Rennes, France
| | - Catherine Paillard
- Department of Paediatric Haematology and Oncology, Strasbourg University Hospital, Strasbourg, France
| | | | | | - Eolia Brissot
- Sorbonne University, Saint-Antoine Hospital, AP-HP, INSERM UMRs 938, Paris, France
| | | | | | | | | | - Jean-Hugues Dalle
- Hôpital Robert Debré, GH APHP Nord - Université de Paris, Paris, France
| | - Mohamad Mohty
- Sorbonne University, Saint-Antoine Hospital, AP-HP, INSERM UMRs 938, Paris, France
| |
Collapse
|
10
|
Dalgaard Mikkelsen M, Barbeyron T, Ficko-Blean E, Naretto A, Larocque R, Genicot S, Roret T, Czjzek M, Meyer A, Michel G. Unveiling the substrate specificity of sulfatases, another important group of carbohydrate active enzymes. Acta Cryst Sect A 2022. [DOI: 10.1107/s2053273322096061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/19/2023]
|
11
|
Garcia M, Rouchy E, Garcia M, Michel G. The network structure of psychopathic personality traits in a community sample of young adult females. Encephale 2022:S0013-7006(22)00101-4. [DOI: 10.1016/j.encep.2022.02.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2021] [Revised: 02/16/2022] [Accepted: 02/18/2022] [Indexed: 10/15/2022]
|
12
|
Courbière B, Drikes B, Gros A, Hamidou Z, Bertrand Y, Gandemer V, Poiree M, Plantaz D, Plat G, Contet A, Ansoborlo S, Paillard C, Kanold J, Auquier P, Michel G. O-267 Uterine volume is dramatically decreased in Stem Cell Hematopoietic Transplantation childhood survivors whatever the conditioning regimen. A case-control MRI study in the L.E.A cohort. Hum Reprod 2022. [DOI: 10.1093/humrep/deac106.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Study question
What is the impact of the type of myeloablative conditioning (MAC) regimen applied for hematopoietic stem cell transplantation (HSCT) on uterine volume of childhood leukemia survivors?
Summary answer
Uterine volume is significantly decreased after HSCT. Not only Total Body Irradiation (TBI), but also high-dose chemotherapy-based regimens containing alkylating agents induce uterine damage.
What is known already
Premature ovarian failure after HSCT is well known, as well as the uterine damage induced by TBI on uterine volume. A few studies have reported smaller uterus after HSCT in women treated with chemotherapy only. In these studies, uterus volume was assessed by a transabdominal and/or transvaginal ultrasonography, and primary diagnosis, age at treatment and chemotherapy regimen were heterogeneous. These preliminary results suggested that alkylating agents could induce uterine damage, as well as they induce fibrosis and vascular damage in ovarian stroma. The impact of chemotherapy on myometrium and uterus is still few investigated.
Study design, size, duration
A prospective multicentric national study was conducted between 2017, November and 2021, June in 16 University Teaching Hospitals that are following more than 4 500 childhood acute leukemia survivors enrolled in the L.E.A cohort. We included 88 adult women treated for a childhood acute leukemia with HSCT and who agreed a pelvic MRI assessment. Every case was matched 1:1 to control women who underwent MRI for benign ovarian cysts or benign pelvic pathology.
Participants/materials, setting, methods
Pelvic MRI scans were performed with a 1.5-T or 3T magnetic resonance scanner, including diffusion-weighted imaging sequences. Scans were centralized for a double-blinded lecture by two radiologists. The main outcome was the uterine volume. The secondary outcomes were uterine body-to-cervix ratio and apparent diffusion coefficient (ADC). Univariate and multivariate analyses have investigated the association of clinical and imaging variables with conditioning regimen and age at HSCT.
Main results and the role of chance
The mean age in HSCT group was 26.5 + 6.3 years. Mean age at HSCT was 9.1 + 0.3 years with a mean follow-up of 16.4 + 0.5 years. Among the 88 women included in HSCT group, two groups of conditioning regimens have been compared to the control group: a chemotherapy-only MAC regimen group with high dose of alkylating agents (n = 34) and one TBI-based regimen group (n = 52). Two MRI scans were not available. Among HSCT group, 75 women were considered as “normally impregnated” by estrogens, by hormone replacement therapy (HRT) for premature ovarian insufficiency (POI) or thanks to a residual ovarian function. Uterine volume was significantly decreased both after chemotherapy-only MAC regimen and after TBI, with respectively 45.3 + 5.6 and 19.6 + 1.9 mL Vs 79.7 + 3.3 mL in control population (p < 0.01). In chemotherapy-only MAC regimen group, uterine volume was dramatically decreased in POI women without HRT compared to those having a hormonal impregnation (15.2 + 2.6 Vs 49.3 + 6 mL, p < 0.05). In contrast, after TBI, uterine volume was similar in all women, with no positive effect of HRT on uterine volume (respectively 16.3 + 2.6 Vs 20.1 + 2.2 mL).
Limitations, reasons for caution
The number of pregnancies obtained spontaneously or after oocyte donation in our study population was too low to evaluate the obstetrical impact of uterine damage caused by non-TBI regimens.
Wider implications of the findings
Our results provide strong evidence that a MAC regimen containing high dose of alkylating agents could induce uterine damage. In these sub-group of women, HRT increases the volume of the uterus compared to non-treated women. After TBI, uterine volume is dramatically decreased, with no benefit of HRT on it.
Trial registration number
NCT 03583294
Collapse
Affiliation(s)
- B Courbière
- AP-HM Hôpital de la Conception / Aix Marseille University, gynecology-obstetrics and reproductive medicine , Marseille, France
| | - B Drikes
- AP-HM Hôpital de La Timone , Radiology, Marseille, France
| | - A Gros
- AP-HM Hôpital de La Timone , Radiology, Marseille, France
| | - Z Hamidou
- Hôpital de la Timone, CEReS Research Unit EA 3279- , Marseille, France
- Departmentof Public Health 3279- , Marseille, France
| | - Y Bertrand
- University Hospital of Lyon , Pediatric hematology , Lyon, France
| | - V Gandemer
- University Hospital of Rennes, Pediatric Hematology and Oncology , Rennes, France
| | - M Poiree
- University Hospital L'Archet , Pediatric Hematology and oncology , Nice, France
| | - D Plantaz
- University Hospital of Grenoble, Pediatric Hematology and Oncology , Grenoble, France
| | - G Plat
- University Hospital of Toulouse, Pediatric Hematology and Oncology , Toulouse, France
| | - A Contet
- Children's Hospital of Brabois , Pediatric Hematology and Oncology , Vandoeuvre-les-Nancy, France
| | - S Ansoborlo
- University Hospital of Bordeaux, Pediatric Hematology and Oncology , Bordeaux, France
| | - C Paillard
- University Hospital of Strasbourg, Pediatric Hematology and Oncology , Strasbourg, France
| | - J Kanold
- University Hospital of Clermont-Ferrand , Pediatric hematology and Oncology , Clermont-Ferrand, France
| | - P Auquier
- APHM Hôpital de la Timone / Aix Marseille University, CEReS Research Unit EA 3279 and Department of Public Health , Marseille, France
| | - G Michel
- La Timone Children's Hospital, Pediatric Hematology- Immunology and Oncology , Marseille, France
| |
Collapse
|
13
|
Greca E, Kacimi SEO, Ghozy S, Wireko AA, Toufik A, Poudel S, Prendi B, Michel G, Michel J. Immunomodulatory effect of different statin regimens on regulatory T-cells among patients with acute coronary syndrome: a systematic review and network meta-analysis of randomized clinical trials. Cardiovasc Res 2022. [DOI: 10.1093/cvr/cvac066.148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Immunomodulatory effect of different statin regimens on regulatory T-cells among patients with acute coronary syndrome: a systematic review and network meta-analysis of randomized clinical trials
Introduction
In patients with acute coronary syndrome (ACS), studies suggest that statin therapy, besides its role in reducing the progression of atherosclerosis through its pharmacological effect, plays a pivotal role in controlling the pathogenesis of ACS through the anti-inflammatory effects of suppressor regulatory T cells (Tregs).
Purpose
We conducted a network meta-analysis (NMA) to determine the effects of low-dose conventional statin therapy (CST) (20 mg/day or less) and high-dose intensive statin therapy (IST) (40 mg/day or more) on the frequency of Tregs and their associated cytokines (IFN-γ, IL-10, TGF-β), compared to placebo.
Methods
The PubMed, Cochrane Library, and EMBASE databases were searched for randomized clinical trials (RCTs) to identify relevant articles published until June 2021. We pooled data extracted from the included studies using the standardized mean difference (SMD). A random-effects model was used to conduct this NMA. Heterogeneity was evaluated using Cochran's Q- and the I2-test. GRADE(Grading of Recommendations, Assessment, Development and Evaluations) was used to assess the study's quality. Data analysis was conducted using R software.
Results
A total of 505 patients were enrolled in the 5 RCTs. The NMA indicated a significant increase in Treg frequency in the CST group compared with the control group (SMD 1.77; 95% CI: 0.77 – 2.76; P-value = 0.0005) and a larger increase in the Treg frequency associated with the IST group compared with the control group (SMD 2.12; 95% CI: 1.15 – 3.10; P-value < 0.0001). However, there was significant heterogeneity and inconsistency among the included studies (τ2 = 0.6096; τ = 0.7808; I2 = 91.2% [80.5%; 96.0%]). When compared to the placebo, both CST and IST increased levels of secreted IL-10 (SMD 2.69; 95% CI: 2.07 – 3.31; P-value < 0.0001 and (SMD 2.14; 95% CI: 1.76 – 2.52; P-value < 0.0001), respectively. In comparison to the control group, CST was associated with increased levels of TGF-β (SMD 3.83; 95% CI: 0.63 – 7.0; P-value = 0.0189). This association was not seen in the IST group. IFN-γ levels decreased significantly in both the IST and CST groups (SMD -1.52; 95% CI: -1.94 – -1.10; P-value < 0.0001) and (SMD -2.34; 95% CI: -2.73 – -1.95; P-value < 0.0001) respectively.
Conclusions
Our study suggests that both high and low dose statin groups showed increased Treg frequency compared to the placebo group. IST showed larger benefits. Statin therapy also increased IL-10 and TGF-β cytokine levels and decreased IFN-γ levels. Therefore, statins have the potential to be the main treatment to reduce the incidence of cardiovascular events and improve cardiac function in patients with ACS through immunomodulatory effect on Treg.
Collapse
Affiliation(s)
- E Greca
- Larkin Community Hospital, Division of Research and Academic Affairs , Miami , United States of America
| | - S E O Kacimi
- Larkin Community Hospital, Division of Research and Academic Affairs , Miami , United States of America
| | - S Ghozy
- Mayo Clinic, Department of Radiology , Rochester , United States of America
| | - A A Wireko
- Sumy State University, Medical Institute , Sumy , Ukraine
| | - A Toufik
- Sumy State University, Medical Institute , Sumy , Ukraine
| | - S Poudel
- Larkin Community Hospital, Division of Research and Academic Affairs , Miami , United States of America
| | - B Prendi
- University Hospital Center Mother Theresa , Tirana , Albania
| | - G Michel
- Larkin Community Hospital, Program Director of Internal Medicine , Miami , United States of America
| | - J Michel
- Larkin Community Hospital, Founder Larkin Health System/Larkin University , Miami , United States of America
| |
Collapse
|
14
|
Garcia M, Rouchy E, Colins O, Andershed H, Michel G. Validation of the French Youth Psychopathic Traits Inventory-Short Version in a general population sample of emerging adults in France. Psychologie Française 2022. [DOI: 10.1016/j.psfr.2022.04.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
15
|
Abstract
AIM The aim of this study was to evaluate the impact of cochlear reimplantation (CR) on hearing performance in children and adults with severe to profound hearing loss. MATERIAL AND METHODS Retrospective observational study. OBJECTIVES The main objective of this study was to determine whether there was a difference in hearing performance before and after CR. Secondary objectives were to analyze reasons for CR; to assess correlations between auditory performance and complete electrode reinsertion during CR, age, gender, explantation-to-CR interval, and interval between first implantation and CR; and to assess difference in APCEI score and the French evaluation protocol for implanted patients before and after CR. RESULTS Comparison of speech perception scores before and after explantation-reimplantation showed no significant difference (P>0.005) at 1 year or at 2 years after CR. In 80% of cases, reimplantation was due to hard implant failure. In other cases, it was undertaken for soft failure (diminished performance but no abnormalities on integrity testing) (8%), medical reasons (6%), or undetermined reasons (6%). There was no significant correlation between auditory performance at 1 or 2 years and complete or incomplete reinsertion of electrodes, age, gender, explantation-to-CR interval, or interval between first implantation and CR (P>0.005). For the adult subgroup, the French evaluation protocol scores did not differ after reimplantation (P=0.62). Likewise, for the child sub-group, APCEI and CAP results did not deteriorate after reimplantation. CONCLUSION Reimplantation had no negative impact on hearing and speech perception, but provided performance equivalent to or better than after initial implantation.
Collapse
Affiliation(s)
- M Durand
- Service d'ORL et de Chirurgie Cervico-Faciale, Centre Hospitalier Universitaire, 1, Place Alexis-Ricordeau, 44093 Nantes Cedex 1, France.
| | - G Michel
- Service d'ORL et de Chirurgie Cervico-Faciale, Centre Hospitalier Universitaire, 1, Place Alexis-Ricordeau, 44093 Nantes Cedex 1, France
| | - J Boyer
- Service d'ORL et de Chirurgie Cervico-Faciale, Centre Hospitalier Universitaire, 1, Place Alexis-Ricordeau, 44093 Nantes Cedex 1, France
| | - P Bordure
- Service d'ORL et de Chirurgie Cervico-Faciale, Centre Hospitalier Universitaire, 1, Place Alexis-Ricordeau, 44093 Nantes Cedex 1, France
| |
Collapse
|
16
|
Lankester AC, Neven B, Mahlaoui N, von Asmuth EGJ, Courteille V, Alligon M, Albert MH, Serra IB, Bader P, Balashov D, Beier R, Bertrand Y, Blanche S, Bordon V, Bredius RG, Cant A, Cavazzana M, Diaz-de-Heredia C, Dogu F, Ehlert K, Entz-Werle N, Fasth A, Ferrua F, Ferster A, Formankova R, Friedrich W, Gonzalez-Vicent M, Gozdzik J, Güngör T, Hoenig M, Ikinciogullari A, Kalwak K, Kansoy S, Kupesiz A, Lanfranchi A, Lindemans CA, Meisel R, Michel G, Miranda NAA, Moraleda J, Moshous D, Pichler H, Rao K, Sedlacek P, Slatter M, Soncini E, Speckmann C, Sundin M, Toren A, Vettenranta K, Worth A, Yeşilipek MA, Zecca M, Porta F, Schulz A, Veys P, Fischer A, Gennery AR. Hematopoietic cell transplantation in severe combined immunodeficiency: The SCETIDE 2006-2014 European cohort. J Allergy Clin Immunol 2021; 149:1744-1754.e8. [PMID: 34718043 DOI: 10.1016/j.jaci.2021.10.017] [Citation(s) in RCA: 42] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2021] [Revised: 10/14/2021] [Accepted: 10/20/2021] [Indexed: 10/20/2022]
Abstract
BACKGROUND Hematopoietic stem cell transplantation (HSCT) represents a curative treatment for patients with severe combined immunodeficiency (SCID), a group of monogenic immune disorders with an otherwise fatal outcome. OBJECTIVE We performed a comprehensive multicenter analysis of genotype-specific HSCT outcome, including detailed analysis of immune reconstitution (IR) and the predictive value for clinical outcome. METHODS HSCT outcome was studied in 338 patients with genetically confirmed SCID who underwent transplantation in 2006-2014 and who were registered in the SCETIDE registry. In a representative subgroup of 152 patients, data on IR and long-term clinical outcome were analyzed. RESULTS Two-year OS was similar with matched family and unrelated donors and better than mismatched donor HSCT (P < .001). The 2-year event-free survival (EFS) was similar in matched and mismatched unrelated donor and less favorable in mismatched related donor (MMRD) HSCT (P < .001). Genetic subgroups did not differ in 2-year OS (P = .1) and EFS (P = .073). In multivariate analysis, pretransplantation infections and use of MMRDs were associated with less favorable OS and EFS. With a median follow-up of 6.2 years (range, 2.0-11.8 years), 73 of 152 patients in the IR cohort were alive and well without Ig dependency. IL-2 receptor gamma chain/Janus kinase 3/IL-7 receptor-deficient SCID, myeloablative conditioning, matched donor HSCT, and naive CD4 T lymphocytes >0.5 × 10e3/μL at +1 year were identified as independent predictors of favorable clinical and immunologic outcome. CONCLUSION Recent advances in HSCT in SCID patients have resulted in improved OS and EFS in all genotypes and donor types. To achieve a favorable long-term outcome, treatment strategies should aim for optimal naive CD4 T lymphocyte regeneration.
Collapse
Affiliation(s)
- Arjan C Lankester
- Pediatric Stem Cell Transplantation Program and Laboratory for Pediatric Immunology, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, The Netherlands.
| | - Benedicte Neven
- Unité d'Immuno-hematologie et Rhumatologie Pédiatrique, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France; Université de Paris, Paris, France; Institut Imagine, INSERM UMR1163, Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Paris, France
| | - Nizar Mahlaoui
- French National Reference Center for Primary Immunodeficiencies (CEREDIH) and European Registry for Stem Cell Transplantation for Primary Immunodeficiencies (SCETIDE), Hôpital Universitaire Necker-Enfants malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Erik G J von Asmuth
- Pediatric Stem Cell Transplantation Program and Laboratory for Pediatric Immunology, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, The Netherlands
| | - Virginie Courteille
- French National Reference Center for Primary Immunodeficiencies (CEREDIH) and European Registry for Stem Cell Transplantation for Primary Immunodeficiencies (SCETIDE), Hôpital Universitaire Necker-Enfants malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Mikael Alligon
- French National Reference Center for Primary Immunodeficiencies (CEREDIH) and European Registry for Stem Cell Transplantation for Primary Immunodeficiencies (SCETIDE), Hôpital Universitaire Necker-Enfants malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Michael H Albert
- Dr von Haunersches University Children's Hospital, Munich, Germany
| | - Isabelle Badell Serra
- Hospital Clínic, Sant Creu i Sant Pau Hospital, Bone Marrow Transplantation Unit, Barcelona, Spain
| | - Peter Bader
- Department for Children and Adolescents Medicine, Division for Stem Cell Transplantation and Immunology, University Hospital Frankfurt, Frankfurt, Germany
| | - Dmitry Balashov
- Department for Hematopoietic Stem Cell Transplantation, Dmitriy Rogachev National Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia
| | - Rita Beier
- Klinik für Pädiatrische Hämatologie und Onkologie, Hannover Medical School, Hannover, Germany
| | - Yves Bertrand
- Institut d'Hématologie et d'Oncologie Pédiatrique, Hospices Civils de Lyon and Université Claude Bernard Lyon 1, Lyon, France
| | - Stephane Blanche
- Unité d'Immuno-hematologie et Rhumatologie Pédiatrique, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Victoria Bordon
- Department of Pediatric Hemato-oncology and Stem Cell Transplant, Ghent University Hospital, Ghent, Belgium
| | - Robbert G Bredius
- Pediatric Stem Cell Transplantation Program and Laboratory for Pediatric Immunology, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, The Netherlands
| | - Andrew Cant
- Translational and Clinical Research Institute, Newcastle University, and the Paediatric Haematopoietic Stem Cell Transplant Unit, Great North Children's Hospital, Newcastle upon Tyne, United Kingdom
| | - Marina Cavazzana
- Université de Paris, Paris, France; Paris Biotherapy Department, Necker Children's Hospital Assistance, Paris, France; Biotherapy Clinical Investigation Center, Assistance Publique Hopitaux de Paris, INSERM, Paris, France; Laboratory of Genomic Dynamics in the Immune System, Institut Imagine, INSERM UMR1163, Paris, France
| | - Cristina Diaz-de-Heredia
- Department of Pediatric Oncology and Hematology, and Hematopoietic Stem Cell Transplantation, Hospital Universitario Vall d'Hebron, Barcelona, Spain
| | - Figen Dogu
- Department of PIA and the BMT Unit, Ankara University, Ankara, Turkey
| | - Karoline Ehlert
- Department of Pediatric Hematology and Oncology, Universitätsklinikum Münster, Münster, Germany; Department of Pediatric Hematology and Oncology, University of Greifswald, Greifswald, Germany
| | - Natacha Entz-Werle
- Pediatric Onco-hematology Department-Pediatrics III, University Hospital of Strasbourg, Strasbourg, France
| | - Anders Fasth
- Department of Pediatrics, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden
| | - Francesca Ferrua
- Pediatric Immunohematology and Bone Marrow Transplantation Unit and the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Alina Ferster
- Department of Hemato-oncology, Hôpital Universitaire des Enfants Reine Fabiola, Brussels, Belgium
| | - Renata Formankova
- Department of Pediatric Hematology and Oncology, Teaching Hospital Motol, 2nd Medical School, Charles University Motol, Prague, Czech Republic
| | - Wilhelm Friedrich
- Department of Pediatrics, University Medical Center Ulm, Ulm, Germany
| | - Marta Gonzalez-Vicent
- Hematopoietic Stem Cell Transplantation and Cellular Therapy Unit, Hospital Infantil Universitario "Niño Jesus," Madrid, Spain
| | - Jolanta Gozdzik
- Department of Clinical Immunology and Transplantation, Jagiellonian University Medical College, Krakow, Poland
| | - Tayfun Güngör
- Department of Hematology, Oncology, Immunology, Gene Therapy and Stem Cell Transplantation, and Children's Research Center (CRC), University Children's Hospital, Zurich, Switzerland
| | - Manfred Hoenig
- Department of Pediatrics, University Medical Center Ulm, Ulm, Germany
| | | | - Krzysztof Kalwak
- Department of Pediatric Hematology, Oncology, and BMT, Wroclaw Medical University, Wroclaw, Poland
| | - Savas Kansoy
- Department of Pediatric Hematology and Oncology, Ege University Hospital, Izmir, Turkey
| | - Alphan Kupesiz
- Department of Pediatrics, Hematology, and Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Arnalda Lanfranchi
- Diagnostic Department, Stem Cell Laboratory, Section of Hematology and Blood Coagulation, Clinical Chemistry Laboratory, ASST Spedali Civili, Brescia, Italy
| | - Caroline A Lindemans
- Department of Stem Cell Transplantation, Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands; Department of Pediatrics, University Medical Center Utrecht, University of Utrecht, Utrecht, The Netherlands
| | - Roland Meisel
- Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, Division of Pediatric Stem Cell Therapy, Heinrich-Heine-University, Düsseldorf, Germany
| | - Gerard Michel
- Service d'Hématologie Immunologie Oncologie Pédiatrique, CHU La Timone, Marseille, France
| | - Nuno A A Miranda
- BMT Unit, Instituto Português de Oncologia de Lisboa, Lisbon, Portugal
| | - Jose Moraleda
- Department of Hematology and Hemotherapy, Hospital Virgen de la Arrixaca-IMIB, Murcia, Spain
| | - Despina Moshous
- Unité d'Immuno-hematologie et Rhumatologie Pédiatrique, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France; Université de Paris, Paris, France; Laboratory of Genomic Dynamics in the Immune System, Institut Imagine, INSERM UMR1163, Paris, France
| | - Herbert Pichler
- Department of Stem Cell Transplantation, Children's Cancer Institute, St Anna Hospital, Vienna, Austria
| | - Kanchan Rao
- Great Ormond Street (GOS) Hospital for Children NHS Foundation Trust and University College London GOS Institute of Child Health, London, United Kingdom
| | - Petr Sedlacek
- Department of Pediatric Hematology and Oncology, Teaching Hospital Motol, 2nd Medical School, Charles University Motol, Prague, Czech Republic
| | - Mary Slatter
- Translational and Clinical Research Institute, Newcastle University, and the Paediatric Haematopoietic Stem Cell Transplant Unit, Great North Children's Hospital, Newcastle upon Tyne, United Kingdom
| | - Elena Soncini
- Pediatric Oncohaematology and BMT Unit, Children's Hospital Brescia, Brescia, Italy
| | - Carsten Speckmann
- Department of Pediatric Hematology and Oncology, Center for Pediatrics and Adolescent Medicine, and Institute for Immunodeficiency, Center for Chronic Immunodeficiency (CCI), Faculty of Medicine, Medical Center, University of Freiburg, Freiburg, Germany
| | - Mikael Sundin
- Section of Pediatric Hematology, Immunology, and HCT, Astrid Lindgren Children's Hospital, Karolinska University Hospital, and Division of Pediatrics, CLINTEC, Karolinska Institutet, Stockholm, Sweden
| | - Amos Toren
- Paediatric Hemato-oncology and BMT, Sheba Medical Center, Tel-Hashomer, Israel
| | - Kim Vettenranta
- University of Helsinki and Children's Hospital, University of Helsinki, Helsinki, Finland
| | - Austen Worth
- Great Ormond Street (GOS) Hospital for Children NHS Foundation Trust and University College London GOS Institute of Child Health, London, United Kingdom
| | - Mehmet A Yeşilipek
- Pediatric Hematology, Oncology, and Pediatric Stem Cell Transplantation Unit, Medicalpark Antalya & Göztepe Hospitals, Antalya, Turkey
| | - Marco Zecca
- Pediatric Hematology/Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Fulvio Porta
- Pediatric Oncohaematology and BMT Unit, Children's Hospital Brescia, Brescia, Italy
| | - Ansgar Schulz
- Department of Pediatrics, University Medical Center Ulm, Ulm, Germany
| | - Paul Veys
- Great Ormond Street (GOS) Hospital for Children NHS Foundation Trust and University College London GOS Institute of Child Health, London, United Kingdom
| | - Alain Fischer
- Unité d'Immuno-hematologie et Rhumatologie Pédiatrique, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France; Université de Paris, Paris, France
| | - Andrew R Gennery
- Translational and Clinical Research Institute, Newcastle University, and the Paediatric Haematopoietic Stem Cell Transplant Unit, Great North Children's Hospital, Newcastle upon Tyne, United Kingdom
| |
Collapse
|
17
|
Qassemyar Q, Michel G, Gianfermi M, Atlan M, Havet E, Luca-Pozner V. Sutureless venous microanastomosis using thermosensitive poloxamer and cyanoacrylate: experimental study on a rat model. J Plast Reconstr Aesthet Surg 2021; 75:433-438. [PMID: 34247962 DOI: 10.1016/j.bjps.2021.05.072] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2020] [Revised: 05/08/2021] [Accepted: 05/28/2021] [Indexed: 02/01/2023]
Abstract
INTRODUCTION Sutureless microvascular anastomoses could simplify the microvascular field, shortening operative time and improving the final outcome. The use of thermosensitive poloxamers (TP407) together with the application of cyanoacrylate as an alternative method for conventional sutures was well-documented for arteries, but not for veins. The purpose of our study was to prove the feasibility of this technique for venous anastomoses and compare it with the traditional hand-sewn technique on a rat model. MATERIALS AND METHODS Twenty male Sprague-Dawley rats that weighed between 265 and 310 g were used. In the sutureless group (SG), 20 left external jugular veins (LEJV) end-to-end anastomoses were performed using a T704 and cyanoacrylate glue. They were compared to 20 right external jugular veins (REJV) anastomoses sutured with conventional 10-0 stitches (control group - CG). Diameters of veins, anastomosis time, and patency rate at 15 days were reported. Foreign body reaction was assessed histologically. RESULTS The mean diameter of the LEJV was 0.94 ± 0.1 mm and 0.95 ± 0.09 mm for the REJV. The mean anastomosis time was 11.9 ± 1.37 min for the SG and 27.75 ± 3.31 min for the CG. In the latter group, the immediate patency rate was 95% and 90% at 15 days. For the SG group, 90% of the anastomoses were patent immediately and 85% at 15 days. CONCLUSION TP407 and cyanoacrylate could offer a fast and reliable technique for sutureless venous anastomoses. Before human application, effectiveness of this method remains to be confirmed in larger animals in a long-term follow-up.
Collapse
Affiliation(s)
- Q Qassemyar
- Department of Plastic and Reconstructive Surgery, University Hospital Armand-Trousseau, 26 avenue du Dr Arnold Netter, 75012 Paris, France; Faculty of Medicine, Sorbonne University, 91 boulevard de l'hôpital, 75013 Paris, France; Anatomy Department, University of Picardie, Rue des Louvels, 80000 Amiens, France
| | - G Michel
- Anatomy Department, University of Picardie, Rue des Louvels, 80000 Amiens, France
| | - M Gianfermi
- Anatomy Department, University of Picardie, Rue des Louvels, 80000 Amiens, France
| | - M Atlan
- Faculty of Medicine, Sorbonne University, 91 boulevard de l'hôpital, 75013 Paris, France; Department of Plastic Surgery, Tenon Hospital, 4 Rue de la Chine, 75020 Paris, France
| | - E Havet
- Anatomy Department, University of Picardie, Rue des Louvels, 80000 Amiens, France
| | - V Luca-Pozner
- Department of Plastic and Reconstructive Surgery, University Hospital Armand-Trousseau, 26 avenue du Dr Arnold Netter, 75012 Paris, France; Faculty of Medicine, Sorbonne University, 91 boulevard de l'hôpital, 75013 Paris, France.
| |
Collapse
|
18
|
Rafii H, Garnier F, Ruggeri A, Ionescu I, Ballot C, Bensoussan D, Chabannon C, Dazey B, De Vos J, Gautier E, Giraud C, Larghero J, Cras A, Mialou V, Persoons V, Pouthier F, Thibert JB, Dalle JH, Michel G, Kenzey C, Volt F, Rocha V, Bay JO, Rubio MT, Faucher C, Marry E, Gluckman E. Umbilical cord blood transplants facilitated by the French cord blood banks network. On behalf of the Agency of Biomedicine, Eurocord and the French society of bone marrow transplant and cell therapy (SFGM-TC). Bone Marrow Transplant 2021; 56:2497-2509. [PMID: 33990703 PMCID: PMC8120495 DOI: 10.1038/s41409-021-01313-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2020] [Revised: 03/04/2021] [Accepted: 04/13/2021] [Indexed: 11/18/2022]
Abstract
The public French Cord Blood Banks Network was established in 1999 with the objective of standardizing the practices governing umbilical cord blood (UCB) banking in France. The Network adopted a strategy to optimize its inventory and improve the quality of its banked units based on a quality improvement process using outcome data regularly provided by Eurocord. This study aimed to describe the results, over 10 years, of UCBT facilitated by a national network that used the same criteria of UCB collection and banking and to assess how modifications of banking criteria and unit selection might influence transplant outcomes. Nine hundred and ninety-nine units (593 single-unit and 203 double-unit grafts) were released by the Network to transplant 796 patients with malignant (83%) and non-malignant (17%) diseases. Median cell dose exceeded 3.5 × 107 TNC/kg in 86%. There was a trend to select units more recently collected and with higher cell dose. Neutrophil engraftment was 88.2% (85.7–90.7) and 79.3% (72.6–86.5) respectively for malignant and non-malignant diseases with a trend to faster recovery with higher cell doses. The respective 3-year transplant-related mortality were 31.1% (27.5–35.1) and 34.3% (27.0–43.5). OS was 49% ± 4 in malignant and 62% ± 4 in non-malignant disorders. In multivariate analysis, cell dose was the only unit-related factor associated with outcomes. Our results reflect the benefit on clinical outcomes of the strategy adopted by the Network to bank units with higher cell counts.
Collapse
Affiliation(s)
- Hanadi Rafii
- Eurocord, Hopital Saint-Louis, AP-HP, Institut de Recherche de Saint-Louis (IRSL) EA3518, Université de Paris, Paris, France. .,Monacord, Centre Scientifique de Monaco, Monaco, Monaco.
| | | | - Annalisa Ruggeri
- Eurocord, Hopital Saint-Louis, AP-HP, Institut de Recherche de Saint-Louis (IRSL) EA3518, Université de Paris, Paris, France.,Haematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Irina Ionescu
- Agency of Biomedecine, Saint Denis La Plaine, France
| | - Caroline Ballot
- Cell Therapy unit, Etablissement Français du Sang Hauts de France Normandie, site de LILLE - Belfort, Lille, France
| | - Danièle Bensoussan
- Tissue Engineering and Cell Therapy unit, Regional University hospital, Nancy, France
| | - Christian Chabannon
- Paoli-Calmettes Institute, Departement of Cancer Biology, Inserm CBT1409, Marseille, France
| | - Bernard Dazey
- Cell Therapy unit, Etablissement Français du Sang, Bordeaux, France
| | - John De Vos
- Cell Therapy unit, University hospital, Montpellier, France
| | - Eric Gautier
- Cell Therapy unit, Etablissement Français du Sang, Créteil, France
| | - Christine Giraud
- Department of Hematology and Cell Therapy, Etablissement Français du Sang, University hospital, Poitiers, France
| | - Jérome Larghero
- Cell Therapy Unit and Cord Blood Bank, AP-HP, Hôpital Saint Louis, Paris, France
| | - Audrey Cras
- Cell Therapy Unit and Cord Blood Bank, AP-HP, Hôpital Saint Louis, Paris, France
| | - Valérie Mialou
- Cell Therapy unit, Etablissement Français du Sang, hopital E. Herriot, Lyon, France
| | - Virginie Persoons
- Cell Therapy and Tissue Engineering unit, Etablissement Français du Sang, Grenoble, France
| | - Fabienne Pouthier
- Cell and Tissue Engineering unit, Etablissement Francais du Sang, Besançon, France
| | | | - Jean-Hugues Dalle
- Hopital Robert Debré, Assistance Publique - Hôpitaux de Paris, Paris, France
| | - Gerard Michel
- Aix-Marseille University and La Timone Children's Hospital, Marseille, France
| | - Chantal Kenzey
- Eurocord, Hopital Saint-Louis, AP-HP, Institut de Recherche de Saint-Louis (IRSL) EA3518, Université de Paris, Paris, France.,Monacord, Centre Scientifique de Monaco, Monaco, Monaco
| | - Fernanda Volt
- Eurocord, Hopital Saint-Louis, AP-HP, Institut de Recherche de Saint-Louis (IRSL) EA3518, Université de Paris, Paris, France.,Monacord, Centre Scientifique de Monaco, Monaco, Monaco
| | - Vanderson Rocha
- Eurocord, Hopital Saint-Louis, AP-HP, Institut de Recherche de Saint-Louis (IRSL) EA3518, Université de Paris, Paris, France.,Department of Hematology, Clinics Hospital, University of São Paulo Medical School, São Paulo, Brazil
| | - Jacques-Olivier Bay
- Department of Hematology and Stem Cell Transplantation, Clermont University, Clermont-Ferrand, France
| | - Marie-Thérèse Rubio
- Department of Hematology and Stem Cell Transplantation, regional university hospital, Nancy, France
| | | | - Evelyne Marry
- Agency of Biomedecine, Saint Denis La Plaine, France
| | - Eliane Gluckman
- Eurocord, Hopital Saint-Louis, AP-HP, Institut de Recherche de Saint-Louis (IRSL) EA3518, Université de Paris, Paris, France.,Monacord, Centre Scientifique de Monaco, Monaco, Monaco
| |
Collapse
|
19
|
Hackstein H, Kalina A, Dorn B, Keil IS, Baal N, Michel G, Brendel C, Neubauer A, Jakob T, Bein G. CD11c + dendritic cells mediate antigen-specific suppression in extracorporeal photopheresis. Clin Exp Immunol 2020; 203:329-339. [PMID: 33073358 PMCID: PMC7806418 DOI: 10.1111/cei.13539] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2020] [Revised: 10/07/2020] [Accepted: 10/11/2020] [Indexed: 01/05/2023] Open
Abstract
Extracorporeal photopheresis (ECP) represents one of the most widespread and effective cell therapies for graft‐versus‐host disease and other T cell‐mediated disorders. However, the key factors affecting the therapeutic efficacy of ECP remain unclear. We hypothesized that therapeutic effects are mediated by ECP‐treated antigen‐presenting dendritic cells (DC). To test this hypothesis, we used the experimental model of contact hypersensitivity (CHS). The ECP’s therapeutic activity improved when the total cell dose of the ECP‐treated cells was increased. We used different haptens during sensitization to demonstrate that the anti‐inflammatory activity of ECP is antigen‐specific. This confirmed the hypothesis that professional antigen‐presenting cells are involved in the mode of action. Also, the ECP’s therapeutic activity was abrogated by the depletion of CD11c+ DC, which represents fewer than 1% of all the ECP‐exposed cells. Finally, we confirm the critical importance of CD11c+ DC for ECP activity by showing that only a few purified CD11c+ DC are sufficient to mediate its therapeutic effect. The finding that ECP‐treated, physiological antigen‐presenting DC alone mediate antigen‐specific modulation of a pathological immune response may result in better‐targeted interventions when treating patients.
Collapse
Affiliation(s)
- H Hackstein
- Department of Transfusion Medicine and Hemostaseology, University Hospital Erlangen, Erlangen, Germany
| | - A Kalina
- Institute for Clinical Immunology and Transfusion Medicine, Justus-Liebig-University, Giessen, Germany
| | - B Dorn
- Department of Dermatology and Allergology, Experimental Dermatology and Allergy Research Group, Justus-Liebig-University, Giessen, Germany
| | - I S Keil
- Institute for Clinical Immunology and Transfusion Medicine, Justus-Liebig-University, Giessen, Germany
| | - N Baal
- Institute for Clinical Immunology and Transfusion Medicine, Justus-Liebig-University, Giessen, Germany
| | - G Michel
- Institute for Clinical Immunology and Transfusion Medicine, Justus-Liebig-University, Giessen, Germany
| | - C Brendel
- Department of Hematology, Oncology, Immunology, Philipps-University, Marburg, Germany
| | - A Neubauer
- Department of Hematology, Oncology, Immunology, Philipps-University, Marburg, Germany
| | - T Jakob
- Department of Dermatology and Allergology, Experimental Dermatology and Allergy Research Group, Justus-Liebig-University, Giessen, Germany
| | - G Bein
- Institute for Clinical Immunology and Transfusion Medicine, Justus-Liebig-University, Giessen, Germany
| |
Collapse
|
20
|
Mollin M, Beaumel S, Vigne B, Brault J, Roux-Buisson N, Rendu J, Barlogis V, Catho G, Dumeril C, Fouyssac F, Monnier D, Gandemer V, Revest M, Brion JP, Bost-Bru C, Jeziorski E, Eitenschenck L, Jarrasse C, Drillon Haus S, Houachée-Chardin M, Hancart M, Michel G, Bertrand Y, Plantaz D, Kelecic J, Traberg R, Kainulainen L, Fauré J, Fieschi F, Stasia MJ. Clinical, functional and genetic characterization of 16 patients suffering from chronic granulomatous disease variants - identification of 11 novel mutations in CYBB. Clin Exp Immunol 2020; 203:247-266. [PMID: 32954498 DOI: 10.1111/cei.13520] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2020] [Revised: 08/25/2020] [Accepted: 09/07/2020] [Indexed: 12/13/2022] Open
Abstract
Chronic granulomatous disease (CGD) is a rare inherited disorder in which phagocytes lack nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity. The most common form is the X-linked CGD (X91-CGD), caused by mutations in the CYBB gene. Clinical, functional and genetic characterizations of 16 CGD cases of male patients and their relatives were performed. We classified them as suffering from different variants of CGD (X910 , X91- or X91+ ), according to NADPH oxidase 2 (NOX2) expression and NADPH oxidase activity in neutrophils. Eleven mutations were novel (nine X910 -CGD and two X91- -CGD). One X910 -CGD was due to a new and extremely rare double missense mutation Thr208Arg-Thr503Ile. We investigated the pathological impact of each single mutation using stable transfection of each mutated cDNA in the NOX2 knock-out PLB-985 cell line. Both mutations leading to X91- -CGD were also novel; one deletion, c.-67delT, was localized in the promoter region of CYBB; the second c.253-1879A>G mutation activates a splicing donor site, which unveils a cryptic acceptor site leading to the inclusion of a 124-nucleotide pseudo-exon between exons 3 and 4 and responsible for the partial loss of NOX2 expression. Both X91- -CGD mutations were characterized by a low cytochrome b558 expression and a faint NADPH oxidase activity. The functional impact of new missense mutations is discussed in the context of a new three-dimensional model of the dehydrogenase domain of NOX2. Our study demonstrates that low NADPH oxidase activity found in both X91- -CGD patients correlates with mild clinical forms of CGD, whereas X910 -CGD and X91+ -CGD cases remain the most clinically severe forms.
Collapse
Affiliation(s)
- M Mollin
- Pôle de Biologie, Centre Hospitalier Universitaire Grenoble Alpes, CGD Diagnosis and Research Centre (CDiReC), Grenoble, France
| | - S Beaumel
- Pôle de Biologie, Centre Hospitalier Universitaire Grenoble Alpes, CGD Diagnosis and Research Centre (CDiReC), Grenoble, France
| | - B Vigne
- Pôle de Biologie, Centre Hospitalier Universitaire Grenoble Alpes, CGD Diagnosis and Research Centre (CDiReC), Grenoble, France
| | - J Brault
- Pôle de Biologie, Centre Hospitalier Universitaire Grenoble Alpes, CGD Diagnosis and Research Centre (CDiReC), Grenoble, France
| | - N Roux-Buisson
- Pôle de Biologie, Centre Hospitalier Universitaire Grenoble Alpes, Laboratoire de Biochimie et Génétique Moléculaire, Grenoble, France.,Grenoble Institut Neurosciences, Université Grenoble Alpes, Inserm U1216, Grenoble, France
| | - J Rendu
- Pôle de Biologie, Centre Hospitalier Universitaire Grenoble Alpes, Laboratoire de Biochimie et Génétique Moléculaire, Grenoble, France.,Grenoble Institut Neurosciences, Université Grenoble Alpes, Inserm U1216, Grenoble, France
| | - V Barlogis
- Service de Pédiatrie et Hématologie Pédiatrique, Centre Hospitalier Universitaire La Timone, Marseille, France
| | - G Catho
- Institut d'Hématologie et d'Oncologie Pédiatrique, Hospices Civiles de Lyon, Lyon, France
| | - C Dumeril
- Service de Pédiatrie, Centre Hospitalier Annecy Genevois, Pringy, France
| | - F Fouyssac
- Département d'Onco-hématologie Pédiatrique, Centre Hospitalier Universitaire de Nancy, Vandoeuvre-lès-Nancy, France
| | - D Monnier
- Laboratoire d'Immunologie Cellulaire, Centre Hospitalier Universitaire Pontchaillou, Rennes, France
| | - V Gandemer
- Service d'Onco-hématologie Pédiatrique, Centre Hospitalier Universitaire de Rennes, Rennes, France
| | - M Revest
- Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, Rennes, France
| | - J-P Brion
- Pôle Médecine Aigue et Communautaire, Service d'Infectiologie, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France
| | - C Bost-Bru
- Département de Pédiatrie, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France
| | - E Jeziorski
- Département Urgences Post-urgences, CHU Montpellier, Pathogenesis and Control of Chronic Infections, INSERM, Université de Montpellier, Montpellier, France
| | - L Eitenschenck
- Service de Pédiatrie, Centre Hospitalier Annecy Genevois, Pringy, France
| | - C Jarrasse
- Service de Pédiatrie, Centre Hospitalier Annecy Genevois, Pringy, France
| | - S Drillon Haus
- Service de Pédiatrie et Onco-hématologie, Centre Hospitalier Universitaire de Strasbourg, Hôpital de Hautepierre, Strasbourg, France
| | - M Houachée-Chardin
- Institut d'Hématologie et d'Oncologie Pédiatrique, Hospices Civiles de Lyon, Lyon, France
| | - M Hancart
- Département Urgences Post-urgences, CHU Montpellier, Pathogenesis and Control of Chronic Infections, INSERM, Université de Montpellier, Montpellier, France
| | - G Michel
- Service de Pédiatrie et Hématologie Pédiatrique, Centre Hospitalier Universitaire La Timone, Marseille, France
| | - Y Bertrand
- Institut d'Hématologie et d'Oncologie Pédiatrique, Hospices Civiles de Lyon, Lyon, France
| | - D Plantaz
- Département de Pédiatrie, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France
| | - J Kelecic
- Klinicki Bolnicki Centar Zagreb, Zagreb, Croatia
| | - R Traberg
- Hospital of Lithuanian University of Health Sciences, Kauno Klinikos, Kaunas, Lithuania
| | - L Kainulainen
- Department of Pediatrics, University Hospital of Turku, Turku, Finland.,Faculty of Medicine Turku, University of Turku, Turku, Finland
| | - J Fauré
- Pôle de Biologie, Centre Hospitalier Universitaire Grenoble Alpes, Laboratoire de Biochimie et Génétique Moléculaire, Grenoble, France.,Grenoble Institut Neurosciences, Université Grenoble Alpes, Inserm U1216, Grenoble, France
| | - F Fieschi
- Univ. Grenoble Alpes, CEA, CNRS, IBS, F-38044, Grenoble, France
| | - M J Stasia
- Pôle de Biologie, Centre Hospitalier Universitaire Grenoble Alpes, CGD Diagnosis and Research Centre (CDiReC), Grenoble, France.,Univ. Grenoble Alpes, CEA, CNRS, IBS, F-38044, Grenoble, France
| |
Collapse
|
21
|
Falcon E, Michel G, Prabhudesai G, Cazaubiel A, Berhanu M, Mordant N, Aumaître S, Bonnefoy F. Saturation of the Inverse Cascade in Surface Gravity-Wave Turbulence. Phys Rev Lett 2020; 125:134501. [PMID: 33034484 DOI: 10.1103/physrevlett.125.134501] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/04/2020] [Accepted: 08/14/2020] [Indexed: 06/11/2023]
Abstract
We report on the observation of surface gravity-wave turbulence at scales larger than the forcing ones in a large basin. In addition to the downscale transfer usually reported in gravity-wave turbulence, an upscale transfer is observed, interpreted as the inverse cascade of weak turbulence theory. A steady state is achieved when the inverse cascade reaches a scale in between the forcing wavelength and the basin size, but far from the latter. This inverse cascade saturation, which depends on the wave steepness, is probably due to the emergence of nonlinear dissipative structures such as sharp-crested waves.
Collapse
Affiliation(s)
- E Falcon
- Université de Paris, Univ Paris Diderot, MSC, UMR 7057 CNRS, F-75 013 Paris, France
| | - G Michel
- Sorbonne Université, IJLRA, UMR 7190 CNRS, F-75 005 Paris, France
| | - G Prabhudesai
- Ecole Normale Supérieure, LPS, UMR 8550 CNRS, F-75 205 Paris, France
| | - A Cazaubiel
- Université de Paris, Univ Paris Diderot, MSC, UMR 7057 CNRS, F-75 013 Paris, France
| | - M Berhanu
- Université de Paris, Univ Paris Diderot, MSC, UMR 7057 CNRS, F-75 013 Paris, France
| | - N Mordant
- Université Grenoble Alpes, LEGI, UMR 5519 CNRS, F-38 000 Grenoble, France
| | - S Aumaître
- CEA-Saclay, Sphynx, DSM, URA 2464 CNRS, F-91 191 Gif-sur-Yvette, France
| | - F Bonnefoy
- Ecole Centrale de Nantes, LHEEA, UMR 6598 CNRS, F-44 321 Nantes, France
| |
Collapse
|
22
|
Giardino S, Latour RP, Aljurf M, Eikema D, Bosman P, Bertrand Y, Tbakhi A, Holter W, Bornhäuser M, Rössig C, Burkhardt B, Zecca M, Afanasyev B, Michel G, Ganser A, Alseraihy A, Ayas M, Uckan‐Cetinkaya D, Bruno B, Patrick K, Bader P, Itälä‐Remes M, Rocha V, Jubert C, Diaz MA, Shaw PJ, Junior LGD, Locatelli F, Kröger N, Faraci M, Pierri F, Lanino E, Miano M, Risitano A, Robin M, Dufour C. Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: A retrospective analysis on behalf of EBMT group. Am J Hematol 2020; 95:809-816. [PMID: 32267023 DOI: 10.1002/ajh.25810] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2020] [Revised: 03/29/2020] [Accepted: 03/30/2020] [Indexed: 12/21/2022]
Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is curative for bone marrow failure in patients with Fanconi anemia (FA), but the presence of a malignant transformation is associated with a poor prognosis and the management of these patients is still challenging. We analyzed outcome of 74 FA patients with a diagnosis of myelodysplastic syndrome (n = 35), acute leukemia (n = 35) or with cytogenetic abnormalities (n = 4), who underwent allo-HSCT from 1999 to 2016 in EBMT network. Type of diagnosis, pre-HSCT cytoreductive therapies and related toxicities, disease status pre-HSCT, donor type, and conditioning regimen were considered as main variables potentially influencing outcome. The 5-year OS and EFS were 42% (30-53%) and 39% (27-51%), respectively. Patients transplanted in CR showed better OS compared with those transplanted in presence of an active malignant disease (OS:71%[48-95] vs 37% [24-50],P = .04), while none of the other variables considered had an impact. Twenty-two patients received pre-HSCT cytoreduction and 9/22 showed a grade 3-4 toxicity, without any lethal event or negative influence on survival after HSCT(OS:toxicity pre-HSCT 48% [20-75%] vs no-toxicity 51% [25-78%],P = .98). The cumulative incidence of day-100 grade II-IV a-GvHD and of 5-year c-GvHD were 38% (26-50%) and 40% (28-52%). Non-relapse-related mortality and incidence of relapse at 5-years were 40% (29-52%) and 21% (11-30%) respectively, without any significant impact of the tested variables. Causes of death were transplant-related events in most patients (34 out of the 42 deaths, 81%). This analysis confirms the poor outcome of transformed FA patients and identifies the importance of achieving CR pre-HSCT, suggesting that, in a newly diagnosed transformed FA patient, a cytoreductive approach pre-HSCT should be considered if a donor have been secured.
Collapse
Affiliation(s)
- Stefano Giardino
- Hematopoietic stem cell transplantation UnitIstituto Giannina Gaslini Genoa Italy
| | - Regis P. Latour
- French reference center for aplastic anemia and PNH;Saint‐Louis HospitalUniversité de Paris Paris France
| | - Mahmoud Aljurf
- King Faisal Hospital and Research Centre Riyadh Saudi Arabia
| | | | | | | | | | | | | | - Claudia Rössig
- Pediatric Hematology and OncologyUniversity Children´s Hospital Muenster Muenster Germany
| | - Birgit Burkhardt
- Pediatric Hematology and OncologyUniversity Children´s Hospital Muenster Muenster Germany
| | - Marco Zecca
- Fondazione IRCSS Policlinico San Matteo Pavia Italy
| | | | | | | | - Amal Alseraihy
- King Faisal Hospital and Research Centre Riyadh Saudi Arabia
| | - Mouhab Ayas
- King Faisal Hospital and Research Centre Riyadh Saudi Arabia
| | | | | | | | - Peter Bader
- Immunologie und IntensivmedizinKlinikum der Johann‐Wolfgang Goethe Universität, Klinik für Kinder‐und Jugendmedizin, Schwerpunkt Stammzelltransplantation Frankfurt am Main Germany
| | | | | | | | - Miguel A. Diaz
- Hospital Infantil Universitario "Niño Jesus" Madrid Spain
| | - Peter J. Shaw
- The Children's Hospital at Westmead Sydney Australia
| | | | - Franco Locatelli
- IRCSS OspedalePediatrico Bambino Gesù, SapienzaUniversity of Rome Rome Italy
| | | | - Maura Faraci
- Hematopoietic stem cell transplantation UnitIstituto Giannina Gaslini Genoa Italy
| | - Filomena Pierri
- Hematopoietic stem cell transplantation UnitIstituto Giannina Gaslini Genoa Italy
| | - Edoardo Lanino
- Hematopoietic stem cell transplantation UnitIstituto Giannina Gaslini Genoa Italy
| | | | | | - Marie Robin
- French reference center for aplastic anemia and PNH;Saint‐Louis HospitalUniversité de Paris Paris France
| | - Carlo Dufour
- UOC EmatologiaIstituto Giannina Gaslini Genoa Italy
| | | |
Collapse
|
23
|
Lelchat F, Mocaer PY, Ojima T, Michel G, Sarthou G, Bucciarelli E, Cérantola S, Colliec-Jouault S, Boisset C, Baudoux AC. Viral degradation of marine bacterial exopolysaccharides. FEMS Microbiol Ecol 2020; 95:5498295. [PMID: 31125051 DOI: 10.1093/femsec/fiz079] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2019] [Accepted: 05/23/2019] [Indexed: 11/14/2022] Open
Abstract
The identification of the mechanisms by which marine dissolved organic matter (DOM) is produced and regenerated is critical to develop robust prediction of ocean carbon cycling. Polysaccharides represent one of the main constituents of marine DOM and their degradation is mainly attributed to polysaccharidases derived from bacteria. Here, we report that marine viruses can depolymerize the exopolysaccharides (EPS) excreted by their hosts using five bacteriophages that infect the notable EPS producer, Cobetia marina DSMZ 4741. Degradation monitorings as assessed by gel electrophoresis and size exclusion chromatography showed that four out of five phages carry structural enzymes that depolymerize purified solution of Cobetia marina EPS. The depolymerization patterns suggest that these putative polysaccharidases are constitutive, endo-acting and functionally diverse. Viral adsorption kinetics indicate that the presence of these enzymes provides a significant advantage for phages to adsorb onto their hosts upon intense EPS production conditions. The experimental demonstration that marine phages can display polysaccharidases active on bacterial EPS lead us to question whether viruses could also contribute to the degradation of marine DOM and modify its bioavailability. Considering the prominence of phages in the ocean, such studies may unveil an important microbial process that affects the marine carbon cycle.
Collapse
Affiliation(s)
- F Lelchat
- Laboratoire BMM, centre Ifremer de Brest, ZI pointe du diable, 29280 Plouzané, France
| | - P Y Mocaer
- Sorbonne Université, CNRS, UMR7144 Adaptation et Diversité en Milieu Marin, Station Biologique de Roscoff, Roscoff, France
| | - T Ojima
- Laboratory of Marine Biotechnology and Microbiology, Graduate School of Fisheries Sciences, Hokkaido University, Minato-cho 3-1-1, Hakodate 041-8611, Japan
| | - G Michel
- Sorbonne Université, CNRS, Laboratoire de Biologie Intégrative des Modèles Marins UMR 8227, Station Biologique de Roscoff, Roscoff, France
| | - G Sarthou
- CNRS, Université de Brest, IRD, Ifremer, UMR 6539/LEMAR/IUEM, Technopôle Brest Iroise, Place Nicolas Copernic, 29280 Plouzané, France
| | - E Bucciarelli
- CNRS, Université de Brest, IRD, Ifremer, UMR 6539/LEMAR/IUEM, Technopôle Brest Iroise, Place Nicolas Copernic, 29280 Plouzané, France
| | - S Cérantola
- Service commun de résonnance magnétique nucléaire, Faculté de science de Brest, Université de Bretagne Occidentale, 6 av. Victor Le Gorgeu, 29238 Brest Cedex 3, France
| | - S Colliec-Jouault
- Laboratoire EM3B, Centre Ifremer Atlantique - Rue de l'Ile d'Yeu - 44311 Nantes, France
| | - C Boisset
- Service commun de chromatographie, CERMAV-CNRS, 601 rue de la chimie, St Martin d'Hère, 38041 Grenoble, France
| | - A-C Baudoux
- Sorbonne Université, CNRS, UMR7144 Adaptation et Diversité en Milieu Marin, Station Biologique de Roscoff, Roscoff, France
| |
Collapse
|
24
|
Derguy C, Bouvard M, Michel G, M’Bailara K. The gap between parents’ knowledge and causal beliefs about etiology of autism: A key variable to understand parents’ anxiety. Eur Psychiatry 2020. [DOI: 10.1016/j.eurpsy.2014.09.195] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
Autism Spectrum Disorders (ASD) are associated with higher levels of anxiety for parents [1]. Provide medical information about autism etiology is the first step to help parents to understand the child disorder and to cope with it. The medical current community accepts that autism is a neurodevelopmental disorder in which genes play a role but that environmental factors likely contribute as well [2]. This conception can meet parent's beliefs constructed on their cultural values and personal experiences. In line with causal attribution theory [3], it is important to consider to parental beliefs because it can impact the treatment choices and the child developmental trajectory [4]. The Main purpose is to evaluate the consistency between parental knowledge and beliefs about ASD etiology. The second purpose is to explore the impact of consistency on parents’ anxiety. We interviewed through open-ended questions 89 parents of ASD children aged between 3 to 10 years about their knowledge and their beliefs about ASD etiology. A content analysis was performed using the Nvivo10 software. Anxiety is evaluated with the subscale of the Hospital Anxiety and Depression Scale (HADS). In agreement with previous work four categories of causes have been identified: biological (BIO), psychological (PSY), multifactorial etiology (BIO + PSY), others (OT). A percentage of 55.1% of parents is consistent between their knowledge and beliefs about ASD etiology while 43.8% are inconsistent. Parent anxiety is significantly higher (T (71.91) = 2.34; P < 0.05) when knowledge and beliefs are inconsistent than when they are consistent. This study demonstrates the deleterious impact of inconsistency between knowledge and beliefs about ASD etiology, on parental anxiety. In order to provide relevant support for parents, information delivered after diagnosis must consider pre-existing parental beliefs. A systematic assessment of parental beliefs would adjust the information provided after the diagnosis.
Collapse
|
25
|
Delehaye F, Habes D, Dourthe ME, Bertrand Y, Michel G, Gaudichon J, Debray D, Nelken B, Pasquet M, Blanche S, Leblanc T. Management of childhood aplastic anemia following liver transplantation for nonviral hepatitis: A French survey. Pediatr Blood Cancer 2020; 67:e28177. [PMID: 31925926 DOI: 10.1002/pbc.28177] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/13/2019] [Revised: 12/18/2019] [Accepted: 12/21/2019] [Indexed: 12/13/2022]
Abstract
BACKGROUND Hepatitis-associated aplastic anemia (AA) is a rare syndrome combining acute hepatitis of variable severity and AA. Hepatitis may be severe enough to require urgent liver transplantation (LT). Herein, we describe clinical presentation and management of a cohort of pediatric patients diagnosed with AA after undergoing LT for nonviral hepatitis. METHODS To describe this rare clinical situation, we performed a national survey and identified nine children treated for AA following LT during the last 10 years in France. RESULTS All patients were treated first for hepatic failure with urgent LT. AA was diagnosed with a median delay of 34 days [21-200] from the diagnosis of hepatitis. Seven children were treated with antithymocyte globulin/cyclosporine, one with CSA alone and one received bone marrow transplantation. At the last visit (median follow-up: 4 years), outcomes were excellent: all patients were alive and in hematological remission (complete remission: 7; partial remission: 2). Immunosuppressive therapy was pursued in all patients due to the liver transplant. No unusual toxicities were reported. CONCLUSION AA after LT is considered a therapeutic challenge. Nevertheless, hematological outcome is good using a standard immunosuppressive approach.
Collapse
Affiliation(s)
- Fanny Delehaye
- Department of Pediatric Hematology and Oncology, University Hospital of Caen, Caen, France
| | - Dalila Habes
- Department of Pediatric Hepatology, AP-HP, Kremlin-Bicêtre Hospital, Le Kremlin-Bicêtre, France
| | - Marie-Emilie Dourthe
- Department of Pediatric Hematology and Immunology, AP-HP, Robert-Debré Hospital, Paris, France
| | - Yves Bertrand
- Institute of Pediatric Hematology and Oncology, Hospices Civils de Lyon, University Claude Bernard Lyon 1, Lyon, France
| | - Gerard Michel
- Department of Pediatric Hematology and Oncology and Research Unit EA 3279, Timone Enfants Hospital and Aix-Marseille University, Marseille, France
| | - Jérémie Gaudichon
- Department of Pediatric Hematology and Oncology, University Hospital of Caen, Caen, France
| | - Dominique Debray
- Unit of Pediatric Hepatology, Reference Center for Rare Pediatric Liver Diseases, Necker-Enfants-Malades University Hospital, Paris, France.,Department of medicine, University of Paris-Descartes, Sorbonne Paris-Cité, Paris, France
| | - Brigitte Nelken
- Department of Pediatric Hematology-Oncology, Jeanne de Flandre Hospital, CHRU, Lille, France
| | - Marlène Pasquet
- Department of Pediatric Hematology and Oncology, University hospital of Toulouse, Toulouse, France
| | - Stéphane Blanche
- Department of Pediatric Hematology, Immunology and Rheumatology, AP-HP, Necker Enfants-Malades Hospital, Paris, France
| | - Thierry Leblanc
- Department of Pediatric Hematology and Immunology, AP-HP, Robert-Debré Hospital, Paris, France
| |
Collapse
|
26
|
Michel G, Martinez-Vinson C, Hugot JP, Ecochard-Dugelay E. Comportement alimentaire des enfants et adolescents atteints d’une maladie inflammatoire chronique en période de rémission clinique et biologique sous biothérapie. NUTR CLIN METAB 2020. [DOI: 10.1016/j.nupar.2020.02.422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
27
|
Boumaza K, Michel G, Salaud C, Bossard C, Espitalier F, Malard O. Peripheral neck nerve tumor: A 73-case study and literature review. Eur Ann Otorhinolaryngol Head Neck Dis 2019; 136:455-460. [PMID: 31537489 DOI: 10.1016/j.anorl.2019.09.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
OBJECTIVES Peripheral neck nerve tumors are rare and mostly benign neoplasms. The exceptional malignant forms are very aggressive, and diagnosis is difficult. The objective of this study was to evaluate diagnostic and therapeutic management and identify possible predictive factors. MATERIAL AND METHODS A retrospective study was conducted of 73 patients treated for peripheral neck nerve tumor between 1995 and 2015. RESULTS Mean age was 44years. The main presenting symptom was a cervical mass, isolated or associated with signs related to the affected nerve structure. Diagnosis was suspected by slow progression of a firm mass, featuring T1 hyposignal and T2 hypersignal on magnetic resonance imaging. Surgery was performed in 99% of cases, completed by adjuvant chemotherapy in case of malignant neuroblastic tumor. Type 1 neurofibromatosis and sudden increase in mass with or without associated pain suggested malignant transformation. Age below 10years suggested neuroblastic tumor. CONCLUSION Neck nerve tumors are very often benign with low degenerative potential. Surgery is the treatment of choice after risk/benefit analysis. However, there is no clearly defined consensus regarding the timing of surgery for these lesions.
Collapse
Affiliation(s)
- K Boumaza
- Service d'ORL et de Chirurgie Cervico-Faciale, CHU de Nantes Hôtel-Dieu, 1, place A. Ricordeau, BP 1005, 44093 Nantes Cedex 01, France
| | - G Michel
- Service d'ORL et de Chirurgie Cervico-Faciale, CHU de Nantes Hôtel-Dieu, 1, place A. Ricordeau, BP 1005, 44093 Nantes Cedex 01, France
| | - C Salaud
- Service de Neurotraumatologie/Neurochirugie, Centre Hospitalier Universitaire de Nantes, Hôtel-Dieu, 1, place A. Ricordeau, BP 1005, 44093 Nantes Cedex 01, France
| | - C Bossard
- Service d'Anatomopathologie, Centre Hospitalier Universitaire de Nantes, Hôtel-Dieu, 1, place A. Ricordeau, BP 1005, 44093 Nantes Cedex 01, France
| | - F Espitalier
- Service d'ORL et de Chirurgie Cervico-Faciale, CHU de Nantes Hôtel-Dieu, 1, place A. Ricordeau, BP 1005, 44093 Nantes Cedex 01, France
| | - O Malard
- Service d'ORL et de Chirurgie Cervico-Faciale, CHU de Nantes Hôtel-Dieu, 1, place A. Ricordeau, BP 1005, 44093 Nantes Cedex 01, France.
| |
Collapse
|
28
|
Kelly K, Daw S, Mauz-Körholz C, Mascarin M, Michel G, Cooper S, Beishuizen A, Leger K, Garaventa A, Buffardi S, Brugières L, Harker-Murray P, Cole P, Drachtman R, Manley T, Francis S, Sacchi M, Leblanc T. RESPONSE-ADAPTED TREATMENT WITH NIVOLUMAB AND BRENTUXIMAB VEDOTIN IN YOUNG PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: CHECKMATE 744 SUBGROUP ANALYSES. Hematol Oncol 2019. [DOI: 10.1002/hon.26_2629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- K.M. Kelly
- Department of Pediatric Oncology; Roswell Park Comprehensive Cancer Center; Buffalo United States
| | - S. Daw
- Paediatric and Adolescent Haemato-Oncology; University College Hospital; London United Kingdom
| | - C. Mauz-Körholz
- Department of Pediatric Hematology and Oncology; University Hospital Justus Liebig University; Giessen Germany
| | - M. Mascarin
- AYA and Pediatric Radiotherapy Unit; IRCCS Centro di Riferimento Oncologico; Aviano Italy
| | - G. Michel
- Service d'Hématologie pédiatrique; CHU de Marseille - Hôpital de la Timone; Maresille France
| | - S. Cooper
- Pediatric Oncology; Johns Hopkins Hospital; Baltimore United States
| | - A. Beishuizen
- Pediatric Oncology/Hematology; Princess Máxima Center for Pediatric Oncology; Utrecht Netherlands
| | - K.J. Leger
- Hematology-Oncology; Seattle Children's Hospital; Seattle United States
| | - A. Garaventa
- UOC Oncologia; Ematologia e Trapianto di Midollo, IRCCS Istituto Giannina Gaslini; Genoa Italy
| | - S. Buffardi
- Paediatric Haemato-Oncology; Santobono-Pausilipon Hospital; Naples Italy
| | - L. Brugières
- Department of Paediatrics; Institut Gustave Roussy; Villejuif France
| | - P. Harker-Murray
- Pediatric Hematology-Oncology; Children's Hospital of Wisconsin; Milwaukee United States
| | - P.D. Cole
- Division of Pediatric Hematology/Oncology; Rutgers Cancer Institute of New Jersey; New Brunswick United States
| | - R.A. Drachtman
- Division of Pediatric Hematology/Oncology; Rutgers Cancer Institute of New Jersey; New Brunswick United States
| | - T. Manley
- Seattle Genetics; Bothell United States
| | - S. Francis
- Bristol-Myers Squibb; Princeton United States
| | - M. Sacchi
- Bristol-Myers Squibb; Princeton United States
| | - T. Leblanc
- Service d'Hématologie Pédiatrique; Hôpital Robert-Debré APHP; Paris France
| |
Collapse
|
29
|
Faraci M, Diesch T, Labopin M, Dalissier A, Lankester A, Gennery A, Sundin M, Uckan-Cetinkaya D, Bierings M, Peters AMJ, Garwer M, Schulz A, Michel G, Giorgiani G, Gruhn B, Locatelli F, Giardino S, Uyttebroeck A, Rialland F, Itäla-Remes M, Dreger P, Shaw PJ, Bordon V, Schlegel PG, Mellgren K, Moraleda JM, Patrick K, Schneider P, Jubert C, Lawitschka A, Salooja N, Basak GW, Corbacioglu S, Duarte R, Bader P. Gonadal Function after Busulfan Compared with Treosulfan in Children and Adolescents Undergoing Allogeneic Hematopoietic Stem Cell Transplant. Biol Blood Marrow Transplant 2019; 25:1786-1791. [PMID: 31082473 DOI: 10.1016/j.bbmt.2019.05.005] [Citation(s) in RCA: 41] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2019] [Revised: 04/27/2019] [Accepted: 05/05/2019] [Indexed: 10/26/2022]
Abstract
Gonadal impairment is an important late effect with a significant impact on quality of life of transplanted patients. The aim of this study was to compare gonadal function after busulfan (Bu) or treosulfan (Treo) conditioning regimens in pre- and postpubertal children. This retrospective, multicenter study included children transplanted in pediatric European Society for Blood and Marrow Transplantation (EBMT) centers between 1992 and 2012 who did not receive gonadotoxic chemoradiotherapy before the transplant. We evaluated 137 patients transplanted in 25 pediatric EBMT centers. Median age at transplant was 11.04 years (range, 5 to 18); 89 patients were boys and 48 girls. Eighty-nine patients were prepubertal at transplant and 48 postpubertal. One hundred eighteen children received Bu and 19 Treo. A higher proportion of girls treated with Treo in the prepubertal stage reached spontaneous puberty compared with those treated with Bu (P = .02). Spontaneous menarche was more frequent after Treo than after Bu (P < .001). Postpubertal boys and girls treated with Treo had significantly lower luteinizing hormone levels (P = .03 and P = .04, respectively) compared with the Bu group. Frequency of gonadal damage associated with Treo was significantly lower than that observed after Bu. These results need to be confirmed in a larger population.
Collapse
Affiliation(s)
- Maura Faraci
- Istituto G. Gaslini, Hematopoietic Stem Cell Transplantation Unit- Hematology-Oncology, Genova, Italy.
| | - Tamara Diesch
- University Children's Hospital Basel, Division of Pediatric Oncology/Hematology, Basel, Switzerland
| | - Myriam Labopin
- Hȏpital Saint-Antoine, Department of Hematology and Cell Therapy, Paris, France
| | - Arnaud Dalissier
- EBMT Paris Study Office/CEREST-TC, Saint Antoine Hospital, Department of Hematology, Paris, France
| | - Arian Lankester
- Willem-Alexander Children's Hospital, Leiden University Medical Center, Department of Pediatric Stem Cell Transplantation, Leiden, Netherlands
| | - Andrew Gennery
- Children's Hospital Newcastle upon Tyne, Pediatric Team Children's BMT Unit, Newcastle upon Tyne, United Kingdom
| | - Mikael Sundin
- Astrid Lindgren Children's Hospital, Karolinska University Hospital, Hematology/Immunology Section, Stockholm, Sweden
| | - Duygu Uckan-Cetinkaya
- Hacettepe University Faculty of Medicine, Bone Marrow Transplantation Unit, Department of Pediatrics, Ankara, Turkey
| | - Marc Bierings
- Princess Maxima Centre for Pediatric Oncology and University Children's Hospital, Utrecht, Netherlands
| | - Anke M J Peters
- Medical Center, University of Freiburg, Center for Pediatrics, Department of Pediatric Hematology and Oncology, Freiburg, Germany
| | - Martina Garwer
- University Hamburg-Eppendorf, Pediatric Hematology Clinic and Policlinic of Oncology, Hamburg-Eppendorf, Germany
| | - Ansgar Schulz
- University Medical Center Ulm, Department of Pediatrics, Ulm, Germany
| | - Gerard Michel
- Hopital d'Enfants de la Timone Marseille, Marseille, France
| | - Giovanna Giorgiani
- Fondazione IRCCS Policlinico San Matteo, Pediatric Hematology-Oncology, Pavia, Italy
| | - Bernd Gruhn
- Jena University Hospital, Department of Pediatrics, Jena, Germany
| | - Franco Locatelli
- IRCSS Ospedale Pediatrico Bambino Gesù, University La Sapienza, Department of Pediatric Hematology/Oncology, Rome, Italy
| | - Stefano Giardino
- Istituto G. Gaslini, Hematopoietic Stem Cell Transplantation Unit- Hematology-Oncology, Genova, Italy
| | - Anne Uyttebroeck
- University Hospitals Leuven, Department of Pediatric Hematology-Oncology, Leuven, Belgium
| | | | | | | | - Peter J Shaw
- The Children's Hospital at Westmead, Division of Blood and Marrow Transplantation, Sydney, Australia
| | - Victoria Bordon
- Ghent University Hospital, Department of Pediatric Hematology, Oncology and SCT, Ghen, Belgium
| | - Paul G Schlegel
- University Children's Hospital Würzburg, Department of Pediatric Oncology, Würzburg, Germany
| | - Karin Mellgren
- The Queen Silvia's Hospital for Children and Adolescents, University of Göteborg, Pediatric Hematology and Oncology, Göteborg, Sweden
| | - Jose M Moraleda
- Hospital Clínico Universitario Virgen de la Arrixaca, IMIB, University of Murcia, Barcelona, Spain
| | - Katharine Patrick
- Sheffield Children's Hospital, Department of Hematology and Oncology, Sheffield, United Kingdom
| | - Pascale Schneider
- Pediatric Hemato-Oncology Department, University Hospital, Rouen, Rouen, France
| | - Charlotte Jubert
- Bordeaux University Hospital, Pediatric BMT Unit, Bordeaux, France
| | - Anita Lawitschka
- St. Anna Children's Hospital, Medical University Vienna, Vienna, Austria
| | - Nina Salooja
- Imperial College London, Department of Medicine, London, United Kingdom
| | - Grzegorz W Basak
- Medical University of Warsaw, Department of Hematology, Oncology and Internal Medicine, Warsaw, Poland
| | - Selim Corbacioglu
- University of Regensburg, Department of Pediatric Hematology, Oncology & Stem Cell Transplantation, Regensburg, Germany
| | - Rafael Duarte
- Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
| | - Peter Bader
- Goethe-Universität, Universitätsklinikum Frankfurt, Frankfurt, Germany
| | | |
Collapse
|
30
|
Carriere C, Michel G, Féart C, Pellay H, Onorato O, Barat P, Thibault H. Relationships between emotional disorders, personality dimensions, and binge eating disorder in French obese adolescents. Arch Pediatr 2019; 26:138-144. [PMID: 30898314 DOI: 10.1016/j.arcped.2019.02.008] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2018] [Revised: 11/26/2018] [Accepted: 02/09/2019] [Indexed: 02/06/2023]
|
31
|
Wäge J, Strassert JFH, Landsberger A, Loick-Wilde N, Schmale O, Stawiarski B, Kreikemeyer B, Michel G, Labrenz M. Microcapillary sampling of Baltic Sea copepod gut microbiomes indicates high variability among individuals and the potential for methane production. FEMS Microbiol Ecol 2019; 95:5347944. [PMID: 30785612 DOI: 10.1093/femsec/fiz024] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2018] [Accepted: 02/19/2019] [Indexed: 11/13/2022] Open
Abstract
The paradox of methane oversaturation in oxygenated surface water has been described in many pelagic systems and still raises the question of the source. Temora sp. and Acartia sp. commonly dominate the surface and subsurface waters of the central Baltic Sea. It is hypothesised that their gut microbiome at least partly contributes to the methane anomaly in this ecosystem. However, the potential pathway for this methane production remains unclear. Using a microcapillary technique, we successfully overcame the challenge of sampling the gut microbiome of copepods <1 mm. 16S rRNA gene amplicon sequencing revealed differences among the dominant bacterial communities associated with Temora sp. (Actinobacteria, Betaproteobacteria and Flavobacteriia) and Acartia sp. (Actinobacteria, Alphaproteobacteria and Betaproteobacteria) and the surrounding water (Proteobacteria, Cyanobacteria and Verrucomicrobia), but also intraspecific variability. In both copepods, gut-specific prokaryotic taxa and indicative species for methane production pathways (methanogenesis, dimethylsulfoniopropionate or methylphosphonate) were present. The relative abundance of archaea and methanogens was investigated using droplet digital polymerase chain reaction and showed a high variability among copepod individuals, underlining intra- and interspecific differences in copepod-associated prokaryotic communities. Overall, this work highlights that the guts of Temora sp. and Acartia sp. have the potential for methane production but are probably no hotspot.
Collapse
Affiliation(s)
- J Wäge
- Leibniz Institute for Baltic Sea Research, Rostock, Germany
| | - J F H Strassert
- Department of Organismal Biology, Uppsala University, Uppsala, Sweden
| | | | - N Loick-Wilde
- Leibniz Institute for Baltic Sea Research, Rostock, Germany
| | - O Schmale
- Leibniz Institute for Baltic Sea Research, Rostock, Germany
| | - B Stawiarski
- Leibniz Institute for Baltic Sea Research, Rostock, Germany
| | - B Kreikemeyer
- University Hospital Rostock, Department of Medical Microbiology and Hospital Hygiene, Rostock, Germany
| | - G Michel
- Transgenic Technologies Charité , Berlin, Germany
| | - M Labrenz
- Leibniz Institute for Baltic Sea Research, Rostock, Germany
| |
Collapse
|
32
|
Michel G, Chini GP. Multiple scales analysis of slow-fast quasi-linear systems. Proc Math Phys Eng Sci 2019; 475:20180630. [PMID: 31007548 DOI: 10.1098/rspa.2018.0630] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2018] [Accepted: 02/07/2019] [Indexed: 11/12/2022] Open
Abstract
This article illustrates the application of multiple scales analysis to two archetypal quasi-linear systems; i.e. to systems involving fast dynamical modes, called fluctuations, that are not directly influenced by fluctuation-fluctuation nonlinearities but nevertheless are strongly coupled to a slow variable whose evolution may be fully nonlinear. In the first case, fast waves drive a slow, spatially inhomogeneous evolution of their celerity field. Multiple scales analysis confirms that, although the energy E, the angular frequency ω and the modal structure of the waves evolve, the wave action E/ω is conserved in the absence of forcing and dissipation. In the second system, the fast modes undergo an instability that is saturated through a feedback on the slow variable. A new multi-scale analysis is developed to treat this case. The key technical point, confirmed by the analysis, is that the fluctuation energy and mode structure evolve slowly to ensure that the slow field remains in a state of near marginal stability. These two model systems appear to be generic, being representative of many if not all quasi-linear systems. In each case, numerical simulations of both the full and reduced dynamical systems are performed to highlight the accuracy and efficiency of the multiple scales approach. Python codes are provided as electronic supplementary material.
Collapse
Affiliation(s)
- G Michel
- Laboratoire de Physique Statistique, École Normale Supérieure, CNRS, Université P. et M. Curie, Université Paris Diderot, Paris 75005, France
| | - G P Chini
- Department of Mechanical Engineering and Program in Integrated Applied Mathematics, University of New Hampshire, Durham, NH 03824, USA
| |
Collapse
|
33
|
Gendre A, Rives P, Michel G, Boutoille D, Espitalier F, Malard O. Intraoperative bacterial analysis in nasal polyposis: Clinical and functional impact. Eur Ann Otorhinolaryngol Head Neck Dis 2019; 136:155-160. [PMID: 30876852 DOI: 10.1016/j.anorl.2019.02.013] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
BACKGROUND The impact of Staphylococcus aureus on onset of nasal polyposis has been the focus of numerous studies, but there have been few studies of other germs found in the ethmoid of operated patients or of their impact on post-operative results. MATERIAL AND METHODS All patients undergoing endoscopic radical ethmoidectomy for nasal polyposis in the teaching hospital of Nantes (France) between 2006 and 2016 had intraoperative ethmoid cavity bacterial sampling. Phenotypic characteristics, pre- and post-operative symptoms and endoscopic findings were analyzed. Mann-Whitney tests and Kruskal-Wallis correlation analysis were used to assess clinical/bacteriological correlations. OBJECTIVES The main objective was to describe bacterial colonization of patients undergoing surgery for nasal polyposis, and to assess correlations with phenotypic features, functional results and postoperative clinical course. RESULTS One hundred and seven patients were included. A total of 26% were not infected, 55% mono-infected and 19% multi-infected. In 27.3%, staphylococci were isolated; in 30.5%, isolates were gram-negative bacilli. There were no significant correlations between presence or type of pathogen and symptom profile. CONCLUSION This study confirmed the high rate of pathogenic bacteria in nasal cavities in case of polyposis, with high frequencies of S. aureus but also of gram-negative bacilli, raising the question of their involvement in the inflammatory reactions underlying the nasal polyposis.
Collapse
Affiliation(s)
- A Gendre
- Service d'ORL et de chirurgie cervico-faciale, centre hospitalier universitaire de Nantes, Hôtel-Dieu, 1, Place A.-Ricordeau, BP 1005, 44093 Nantes Cedex 01, France
| | - P Rives
- Service d'ORL et de chirurgie cervico-faciale, centre hospitalier universitaire de Nantes, Hôtel-Dieu, 1, Place A.-Ricordeau, BP 1005, 44093 Nantes Cedex 01, France
| | - G Michel
- Service d'ORL et de chirurgie cervico-faciale, centre hospitalier universitaire de Nantes, Hôtel-Dieu, 1, Place A.-Ricordeau, BP 1005, 44093 Nantes Cedex 01, France
| | - D Boutoille
- Service des maladies infectieuses, centre hospitalier universitaire de Nantes, Hôtel-Dieu, 1, Place A.-Ricordeau, BP 1005, 44093 Nantes Cedex 01, France
| | - F Espitalier
- Service d'ORL et de chirurgie cervico-faciale, centre hospitalier universitaire de Nantes, Hôtel-Dieu, 1, Place A.-Ricordeau, BP 1005, 44093 Nantes Cedex 01, France
| | - O Malard
- Service d'ORL et de chirurgie cervico-faciale, centre hospitalier universitaire de Nantes, Hôtel-Dieu, 1, Place A.-Ricordeau, BP 1005, 44093 Nantes Cedex 01, France.
| |
Collapse
|
34
|
Malard O, Michel G, Espitalier F. Outpatient management in plastic and reconstructive head and neck surgery in France. Eur Ann Otorhinolaryngol Head Neck Dis 2019; 136:29-32. [DOI: 10.1016/j.anorl.2018.11.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
35
|
Furtado-Silva JM, Paviglianiti A, Ruggeri A, Boelens JJ, Veys P, Ahmari AA, Zecca M, Locatelli F, Michel G, Volt F, Kenzey C, Sedlacek P, Rao K, Lankester A, Gluckman E, Rocha V. Risk factors affecting outcome of unrelated cord blood transplantation for children with familial haemophagocytic lymphohistiocytosis. Br J Haematol 2018; 184:397-404. [PMID: 30460979 DOI: 10.1111/bjh.15642] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2018] [Accepted: 08/24/2018] [Indexed: 11/27/2022]
Abstract
Allogeneic haematopoietic stem cell transplantation is still the only available curative option for Familial Haemophagocytic Lymphohistiocytosis (FHLH). Most studies report outcomes after bone marrow or peripheral blood stem cell transplantation. We analysed the outcomes of 118 children with FHLH undergoing single-unit umbilical cord blood transplantation performed from 1996 to 2014. Myeloablative conditioning regimen was given to 90% of the patients, and was mostly busulfan-based (n = 81, 76%), including anti-thymocyte globulin or alemtuzumab (n = 102, 86%). The cumulative incidence of Day 60 neutrophil engraftment was 85%; and that of non-relapse mortality and acute graft-versus-host disease (GvHD) was 21% and 33% at 100 days, respectively. The 6-year cumulative incidence of chronic GvHD was 17% and the 6-year probability of overall survival was 55%. In multivariate analysis, children receiving a graft with a total nucleated cell dose greater than 9·9 × 107 /kg had a better overall survival (hazard ratio [HR]: 0·49, 95% CI: 0·27-0·88, P = 0·02). Degree of human leucocyte antigen (HLA) matching was associated with improved disease-free survival (5/6 vs. 6/6 HR: 2·11, 95% confidence interval [CI]: 1·01-4·4, P = 0·05 and ≤4/6 vs. 6/6, HR: 2·82, CI: 1·27-6·23, P = 0·01). Umbilical cord blood transplantation with a high cell dose and good HLA match is a suitable alternative option to haematopoietic stem cell transplantation in children with FHLH who lack a HLA-matched donor.
Collapse
Affiliation(s)
| | - Annalisa Paviglianiti
- Eurocord, Hôpital Saint Louis, Paris, France.,Monacord, Centre Scientifique de Monaco, Monaco, Monaco
| | - Annalisa Ruggeri
- Eurocord, Hôpital Saint Louis, Paris, France.,Monacord, Centre Scientifique de Monaco, Monaco, Monaco.,Department of Paediatric Haematology and Oncology, Instituto di Ricovero e Cura a Carattere Scientifico (IRCCS) "Bambino Gesù" Children's Hospital, Rome, Italy.,Department of Paediatric Sciences, University of Pavia, Pavia, Italy
| | - Jaap Jan Boelens
- Paediatric Blood and Marrow Transplantation Programme, Paediatric Blood and Marrow Transplantation Programme University Hospital Utrecht, Utrecht, The Netherlands
| | - Paul Veys
- Bone Marrow Transplant Department, Great Ormond Street Hospital NHS Trust, London, UK
| | - Ali Abdallah Ahmari
- Department of Paediatric Haematology and Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
| | - Marco Zecca
- Paediatric Haematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Franco Locatelli
- Department of Paediatric Haematology and Oncology, Instituto di Ricovero e Cura a Carattere Scientifico (IRCCS) "Bambino Gesù" Children's Hospital, Rome, Italy.,Department of Paediatric Sciences, University of Pavia, Pavia, Italy
| | - Gerard Michel
- Department of Paediatric Haematology and Oncology, Hopital d'Enfants de la Timone, CHU, Marseille, France
| | - Fernanda Volt
- Eurocord, Hôpital Saint Louis, Paris, France.,Monacord, Centre Scientifique de Monaco, Monaco, Monaco
| | - Chantal Kenzey
- Eurocord, Hôpital Saint Louis, Paris, France.,Monacord, Centre Scientifique de Monaco, Monaco, Monaco
| | - Petr Sedlacek
- Department of Paediatric Haematology and Oncology, University Hospital Motol, Prague, Czech Republic
| | - Kanchan Rao
- Bone Marrow Transplant Department, Great Ormond Street Hospital NHS Trust, London, UK
| | - Arjan Lankester
- Department of Paediatrics, Leiden University Medical Centre, Leiden, The Netherlands
| | - Eliane Gluckman
- Eurocord, Hôpital Saint Louis, Paris, France.,Monacord, Centre Scientifique de Monaco, Monaco, Monaco
| | - Vanderson Rocha
- Eurocord, Hôpital Saint Louis, Paris, France.,Monacord, Centre Scientifique de Monaco, Monaco, Monaco.,Haematology, Transfusion and Cell therapy service, Universidade de São Paulo, São Paulo, Brazil.,Haematology Unit, Churchill Hospital, University of Oxford, Oxford, UK
| | | |
Collapse
|
36
|
Kelada L, Wakefield CE, Doolan EL, Drew D, Wiener L, Michel G, Cohn RJ. Grandparents of children with cancer: a controlled comparison of perceived family functioning. Support Care Cancer 2018; 27:2087-2094. [PMID: 30229340 DOI: 10.1007/s00520-018-4468-7] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2018] [Accepted: 09/10/2018] [Indexed: 12/01/2022]
Abstract
PURPOSE Grandparents can be profoundly emotionally affected when a grandchild is diagnosed with cancer. They also often provide invaluable support for the family (e.g., caring for the sick child and/or siblings). Multigenerational family functioning may therefore change. Limited research has assessed grandparents' perspectives after their grandchild is diagnosed with cancer. In this study, we aimed to (1) assess differences in perceived family functioning among grandparents of a child with cancer and grandparents of healthy children and (2) assess the cancer-specific and demographic factors related to perceived family functioning in grandparents of a grandchild with cancer. PROCEDURE Grandparents of a child with cancer (n = 89) and grandparents of healthy children (n = 133) completed the general functioning, communication, and problem-solving scales of the Family Assessment Device. We used multilevel models with a random intercept to detect (1) between-group differences and (2) identify factors related to perceived family functioning among grandparents with a grandchild with cancer. RESULTS Grandparents with a grandchild with cancer reported poorer family functioning than grandparents with healthy grandchildren. Among the grandparents with a grandchild with cancer, impairments in family functioning were correlated with fewer years since diagnosis, providing care to their sick grandchild and/or siblings and living far away from the sick grandchild. CONCLUSIONS The detrimental impact of childhood cancer likely extends beyond the immediate family members. Including grandparents in interventions-beginning at diagnosis-to reduce distress and increase cohesion for families of a child with cancer is warranted, particularly for grandparents who provide care to their sick grandchild or siblings.
Collapse
Affiliation(s)
- Lauren Kelada
- School of Women's and Children's Health, UNSW Sydney, Kensington, NSW, 2031, Australia. .,Kids Cancer Centre, Sydney Children's Hospital, High Street, Randwick, NSW, 2031, Australia.
| | - C E Wakefield
- School of Women's and Children's Health, UNSW Sydney, Kensington, NSW, 2031, Australia.,Kids Cancer Centre, Sydney Children's Hospital, High Street, Randwick, NSW, 2031, Australia
| | - E L Doolan
- School of Women's and Children's Health, UNSW Sydney, Kensington, NSW, 2031, Australia.,Kids Cancer Centre, Sydney Children's Hospital, High Street, Randwick, NSW, 2031, Australia
| | - D Drew
- Kids Cancer Centre, Sydney Children's Hospital, High Street, Randwick, NSW, 2031, Australia
| | - L Wiener
- Behavioral Health Core, National Cancer Institute, Bethesda, MD, 20892, USA
| | - G Michel
- Department of Health Sciences and Health Policy, University of Lucerne, Frohburgstrasse 3, 6002, Lucerne, Switzerland.,Institute of Social and Preventive Medicine, University of Bern, Finkenhubelweg 11, 3012, Bern, Switzerland
| | - R J Cohn
- School of Women's and Children's Health, UNSW Sydney, Kensington, NSW, 2031, Australia.,Kids Cancer Centre, Sydney Children's Hospital, High Street, Randwick, NSW, 2031, Australia
| |
Collapse
|
37
|
Bonaventure A, Orsi L, Rudant J, Goujon-Bellec S, Leverger G, Baruchel A, Bertrand Y, Nelken B, Pasquet M, Michel G, Sirvent N, Chastagner P, Ducassou S, Thomas C, Besse C, Hémon D, Clavel J. Genetic polymorphisms of Th2 interleukins, history of asthma or eczema and childhood acute lymphoid leukaemia: Findings from the ESCALE study (SFCE). Cancer Epidemiol 2018; 55:96-103. [PMID: 29883839 DOI: 10.1016/j.canep.2018.05.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2018] [Revised: 05/03/2018] [Accepted: 05/07/2018] [Indexed: 01/15/2023]
Abstract
BACKGROUND Previous studies on the putative role of allergy in the aetiology of childhood leukaemia have reported contradictory results. The present study aimed to analyse the relation between a medical history of asthma or eczema and childhood acute lymphoid leukaemia (ALL) in light of potential candidate gene-environment interactions. METHODS Analyses were based on a subset of 434 cases of ALL and 442 controls successfully genotyped and of European ancestry children enrolled in a French population-based case-control study conducted in 2003-2004. Information about medical history was obtained during a standardized interview with the mothers. Candidate polymorphisms in genes of the Th2 cytokines IL4, IL10, IL13 and IL4-receptor, were genotyped or imputed. RESULTS None of the variant alleles were directly associated with childhood acute lymphoid leukaemia. A medical history of asthma or eczema was reported more often in the control group (OR = 0.7 [0.5-1.0]). This association was mostly seen in the group of children not carrying the IL13-rs20541 variant allele (Interaction Odds Ratio IOR 1.9, p-interaction = 0.07) and in those carrying the IL10 triple variant haplotype (IOR 0.5, p-interaction = 0.04). No interaction was observed with the candidate polymorphisms in IL4 and IL4R. CONCLUSION This study provides a new insight into the relationship between allergic symptoms and childhood acute lymphoid leukaemia, by suggesting this inverse association could be limited to children carrying certain genetic polymorphisms. If confirmed, these results could help better understand the biological mechanisms involved in the development of childhood acute lymphoid leukaemia.
Collapse
Affiliation(s)
- A Bonaventure
- INSERM, Université Paris-Descartes, Université Sorbonne-Paris-Cité, CRESS U1153, EPICEA-Epidémiologie des cancers de l'enfant et de l'adolescent, Villejuif, France; INSERM, RNCE-National Registry of Childhood Cancers, Villejuif, France; Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom.
| | - L Orsi
- INSERM, Université Paris-Descartes, Université Sorbonne-Paris-Cité, CRESS U1153, EPICEA-Epidémiologie des cancers de l'enfant et de l'adolescent, Villejuif, France
| | - J Rudant
- INSERM, Université Paris-Descartes, Université Sorbonne-Paris-Cité, CRESS U1153, EPICEA-Epidémiologie des cancers de l'enfant et de l'adolescent, Villejuif, France; INSERM, RNCE-National Registry of Childhood Cancers, Villejuif, France
| | - S Goujon-Bellec
- INSERM, Université Paris-Descartes, Université Sorbonne-Paris-Cité, CRESS U1153, EPICEA-Epidémiologie des cancers de l'enfant et de l'adolescent, Villejuif, France; INSERM, RNCE-National Registry of Childhood Cancers, Villejuif, France
| | - G Leverger
- AP-HP, Hôpital Armand Trousseau, Université Paris 6 Pierre et Marie Curie, Paris, France
| | - A Baruchel
- AP-HP, Hôpital Robert Debré, Université Paris 7 Denis Diderot, Paris, France
| | - Y Bertrand
- Institut d'Hémato-Oncologie Pédiatrique, Lyon, France
| | - B Nelken
- CHU de Lille, Hôpital Jeanne de Flandre, Lille, France
| | - M Pasquet
- Hôpital des Enfants, Toulouse, France
| | - G Michel
- AP-HM, Hôpital la Timone, Marseille, France
| | - N Sirvent
- Hôpital Arnaud de Villeneuve, CHRU, Montpellier, France
| | | | - S Ducassou
- Haematology and Oncology, Childrens' Hospital, Pellegrin, Bordeaux University Hospital, Bordeaux, France
| | - C Thomas
- Service d'onco-hématologie pédiatrique, CHU de Nantes, France
| | - C Besse
- Commissariat à l'Energie Atomique (CEA) Genomics Institute-Centre National de Génotypage, Evry Cedex, France
| | - D Hémon
- INSERM, Université Paris-Descartes, Université Sorbonne-Paris-Cité, CRESS U1153, EPICEA-Epidémiologie des cancers de l'enfant et de l'adolescent, Villejuif, France
| | - J Clavel
- INSERM, Université Paris-Descartes, Université Sorbonne-Paris-Cité, CRESS U1153, EPICEA-Epidémiologie des cancers de l'enfant et de l'adolescent, Villejuif, France; INSERM, RNCE-National Registry of Childhood Cancers, Villejuif, France
| |
Collapse
|
38
|
van den Broek BTA, Page K, Paviglianiti A, Hol J, Allewelt H, Volt F, Michel G, Diaz MA, Bordon V, O'Brien T, Shaw PJ, Kenzey C, Al-Seraihy A, van Hasselt PM, Gennery AR, Gluckman E, Rocha V, Ruggeri A, Kurtzberg J, Boelens JJ. Early and late outcomes after cord blood transplantation for pediatric patients with inherited leukodystrophies. Blood Adv 2018; 2:49-60. [PMID: 29344584 PMCID: PMC5761624 DOI: 10.1182/bloodadvances.2017010645] [Citation(s) in RCA: 36] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2017] [Accepted: 11/28/2017] [Indexed: 12/15/2022] Open
Abstract
Leukodystrophies (LD) are devastating inherited disorders leading to rapid neurological deterioration and premature death. Hematopoietic stem cell transplantation (HSCT) can halt disease progression for selected LD. Cord blood is a common donor source for transplantation of these patients because it is rapidly available and can be used without full HLA matching. However, precise recommendations allowing care providers to identify patients who benefit from HSCT are lacking. In this study, we define risk factors and describe the early and late outcomes of 169 patients with globoid cell leukodystrophy, X-linked adrenoleukodystrophy, and metachromatic leukodystrophy undergoing cord blood transplantation (CBT) at an European Society for Blood and Marrow Transplantation center or at Duke University Medical Center from 1996 to 2013. Factors associated with higher overall survival (OS) included presymptomatic status (77% vs 49%; P = .006), well-matched (≤1 HLA mismatch) CB units (71% vs 54%; P = .009), and performance status (PS) of >80 vs <60 or 60 to 80 (69% vs 32% and 55%, respectively; P = .003). For patients with PS≤60 (n = 20) or 60 to 80 (n = 24) pre-CBT, only 4 (9%) showed improvement. Of the survivors with PS >80 pre-CBT, 50% remained stable, 20% declined to 60 to 80, and 30% to <60. Overall, an encouraging OS was found for LD patients after CBT, especially for those who are presymptomatic before CBT and received adequately dosed grafts. Early identification and fast referral to a specialized center may lead to earlier treatment and, subsequently, to improved outcomes.
Collapse
Affiliation(s)
- Brigitte T A van den Broek
- Blood and Marrow Transplantation Program
- Laboratory for Translational Immunology, and
- Sylvia Toth Center for Multidisciplinary Follow Up After Hematopoietic Cell Transplantation, UMC Utrecht, Utrecht, The Netherlands
| | - Kristin Page
- Pediatric Blood and Marrow Transplantation Program, Duke University Medical Center, Durham, NC
| | | | | | - Heather Allewelt
- Pediatric Blood and Marrow Transplantation Program, Duke University Medical Center, Durham, NC
| | | | | | | | - Victoria Bordon
- Blood and Marrow Transplantation Program, Universiteits Ziekenhuis Gent, Gent, Belgium
| | | | - Peter J Shaw
- Children's Hospital at Westmead, Sydney, Australia
| | | | - Amal Al-Seraihy
- King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| | - Peter M van Hasselt
- Sylvia Toth Center for Multidisciplinary Follow Up After Hematopoietic Cell Transplantation, UMC Utrecht, Utrecht, The Netherlands
| | - Andrew R Gennery
- Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom; and
| | | | | | | | | | - Jaap Jan Boelens
- Blood and Marrow Transplantation Program
- Laboratory for Translational Immunology, and
- Sylvia Toth Center for Multidisciplinary Follow Up After Hematopoietic Cell Transplantation, UMC Utrecht, Utrecht, The Netherlands
| |
Collapse
|
39
|
Paviglianiti A, Dalle JH, Ayas M, Boelens JJ, Volt F, Iori AP, de Souza MP, Diaz MA, Michel G, Locatelli F, Jubert C, Yakoub-Agha I, Bittencourt H, Bertrand Y, Kenzey C, Tozatto Maio K, Hayashi H, Rocha V, Bader P, Gluckman E, Ruggeri A. Low Body Mass Index Is Associated with Increased Risk of Acute GVHD after Umbilical Cord Blood Transplantation in Children and Young Adults with Acute Leukemia: A Study on Behalf of Eurocord and the EBMT Pediatric Disease Working Party. Biol Blood Marrow Transplant 2017; 24:799-805. [PMID: 29288817 DOI: 10.1016/j.bbmt.2017.12.790] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2017] [Accepted: 12/19/2017] [Indexed: 01/19/2023]
Abstract
Body mass index (BMI) may influence outcomes after allogeneic hematopoietic stem cell transplantation (HSCT). However, the impact of BMI on survival in children undergoing HSCT is not well defined, with conflicting results being reported on this issue. We analyzed 855 patients age 2 to 20 years with diagnosis of acute leukemia who underwent umbilical cord blood transplantation (UCBT) from 1990 to 2015. Patients were classified according to BMI as normal (fifth to 85th percentile), underweight (less than fifth percentile), overweight (85th to 95th percentile), and obese (>95th percentile) using growth charts for age and sex. All patients received single-unit UCBT after a myeloablative conditioning regimen. Diagnosis was acute lymphoblastic leukemia in 68% of the patients. Sixty-one percent of patients (n = 523) were in the normal BMI category, 11% (n = 96) were underweight, 16% (n = 137) overweight, and 12% (n = 99) obese. The cumulative incidence of grade II to IV acute graft-versus-host disease (aGVHD) was 35% (32% to 38%). According to pretransplantation BMI, aGVHD was 46% (33% to 59%) for underweight, 34% (31% to 42%) for normal, 36% (18% to 38%) for overweight, and 27% (15% to 37%) for obese (P = .04). In multivariate analysis, a BMI less than the fifth percentile was associated with higher incidence of acute grade II to IV GVHD compared with normal-BMI patients (hazard ratio, 1.61; 95% confidence interval, 1.15 to 2.26; P = .006). Our results show that being underweight at the time of transplantation is associated with an increased risk of aGVHD, highlighting the importance of nutritional status before UCBT.
Collapse
Affiliation(s)
- Annalisa Paviglianiti
- Eurocord, Hôpital Saint Louis, Paris, France; Monacord, Centre Scientifique de Monaco, Monaco, Monaco.
| | - Jean Hugues Dalle
- Pediatric Hematology Department, Hospital Robert Debré, Paris, Paris 7-Paris Diderot University, Paris, France
| | - Mouhab Ayas
- Pediatric Stem Cell Transplant, Department of Pediatric Hematology Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| | - Jan Jaap Boelens
- Department of Pediatrics, Pediatric Blood and Marrow Transplantation Program, University Medical Center, Utrecht, the Netherlands
| | - Fernanda Volt
- Eurocord, Hôpital Saint Louis, Paris, France; Monacord, Centre Scientifique de Monaco, Monaco, Monaco
| | - Anna Paola Iori
- Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | | | - Miguel Angel Diaz
- Stem Cell Transplant Unit, Hospital Universitario Niño Jesus, Madrid, Spain
| | - Gerard Michel
- Department of Pediatric Hematology and Oncology, Timone Enfants Hospital, APHM and Aix Marseille Université, Marseille, France
| | - Franco Locatelli
- Department of Paediatric Hematology and Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) "Bambino Gesù" Children's Hospital, Rome, Italy; Department of Pediatric Sciences, University of Pavia, Rome, Italy
| | - Charlotte Jubert
- Pediatric Hematology Department, Bordeaux-Hospital, Bordeaux University, Lille, France
| | | | - Henrique Bittencourt
- Department of Pediatrics, Charles-Bruneau Cancer Center, CHU Sainte-Justine, Montreal, Quebec, Canada; Department of Pediatrics, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada
| | - Yves Bertrand
- Department of Child Hematology and Oncology, IHOP University Hospital, Hospices Civils de Lyon, Lyon, France
| | - Chantal Kenzey
- Eurocord, Hôpital Saint Louis, Paris, France; Monacord, Centre Scientifique de Monaco, Monaco, Monaco
| | - Karina Tozatto Maio
- Eurocord, Hôpital Saint Louis, Paris, France; Monacord, Centre Scientifique de Monaco, Monaco, Monaco
| | - Hiromi Hayashi
- Eurocord, Hôpital Saint Louis, Paris, France; Monacord, Centre Scientifique de Monaco, Monaco, Monaco
| | - Vanderson Rocha
- Eurocord, Hôpital Saint Louis, Paris, France; Monacord, Centre Scientifique de Monaco, Monaco, Monaco; Serviço de Hematologia, Hemoterapia e Terapia Celular, Hospital das Clinicas, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
| | - Peter Bader
- Division for Stem Cell Transplantation and Immunology, Department for Children and Adolescents, University Hospital, Goethe University, Frankfurt am Main, Germany
| | - Eliane Gluckman
- Eurocord, Hôpital Saint Louis, Paris, France; Monacord, Centre Scientifique de Monaco, Monaco, Monaco
| | - Annalisa Ruggeri
- Eurocord, Hôpital Saint Louis, Paris, France; Monacord, Centre Scientifique de Monaco, Monaco, Monaco; Hopital Saint Antoine, Service d'Hématologie et thérapie cellulaire, Paris, France
| |
Collapse
|
40
|
Montagner A, Michel G, Fouché E, Régnier M, Polizzi A, Lukowicz C, Amiel A, Lasserre F, Naylies C, Canlet C, Tremblay-Franco M, Debrauwer L, Lippi Y, Wahli W, Guillou H. PPARβ hépatocytaire est un senseur circadien des acides gras alimentaires. NUTR CLIN METAB 2017. [DOI: 10.1016/j.nupar.2017.06.062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
41
|
Almousawi HS, Assaf N, Herlin C, Alharbi M, Michel G, Sinna R, Dast S. Dorsal median lipectomy (the arrow technique): A new approach for the treatment of the circumferential truncal skin and fatty tissue excess. ANN CHIR PLAST ESTH 2017; 62:659-663. [PMID: 28778501 DOI: 10.1016/j.anplas.2017.06.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2017] [Accepted: 06/29/2017] [Indexed: 11/17/2022]
Abstract
The increase in the number of patients who undergo massive weight loss surgery has led to an increasing number of patients who complain of circumferential abdominal skin and soft tissue excess. Currently, the only surgical option to treat soft tissue excess is vertical median abdominal lipectomy (fleur-de-lys technique). However, many patients are reluctant to undergo this surgery because of the position of the scar. We presented a new surgical approach to manage circumferential excess - dorsal median lipectomy (arrow technique) - in which the dorsal scar is well-tolerated by patients.
Collapse
Affiliation(s)
- H S Almousawi
- Department of plastic reconstructive and aesthetic surgery, university hospital of Picardie, 80054 Amiens, France
| | - N Assaf
- Department of plastic reconstructive and aesthetic surgery, university hospital of Picardie, 80054 Amiens, France
| | - C Herlin
- Department of plastic and craniofacial surgery, university hospital of Montpellier, Montpellier, France
| | - M Alharbi
- Department of plastic reconstructive and aesthetic surgery, university hospital of Picardie, 80054 Amiens, France
| | - G Michel
- Department of plastic reconstructive and aesthetic surgery, university hospital of Picardie, 80054 Amiens, France
| | - R Sinna
- Department of plastic reconstructive and aesthetic surgery, university hospital of Picardie, 80054 Amiens, France.
| | - S Dast
- Department of plastic reconstructive and aesthetic surgery, university hospital of Picardie, 80054 Amiens, France
| |
Collapse
|
42
|
Galéra C, Salla J, Montagni I, Hanne-Poujade S, Salamon R, Grondin O, Guichard E, Bouvard MP, Tzourio C, Michel G. Stress, attention deficit hyperactivity disorder (ADHD) symptoms and tobacco smoking: The i-Share study. Eur Psychiatry 2017; 45:221-226. [PMID: 28957791 DOI: 10.1016/j.eurpsy.2017.07.007] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/15/2017] [Revised: 07/17/2017] [Accepted: 07/18/2017] [Indexed: 10/19/2022] Open
Abstract
BACKGROUND The contribution of mental health to the risk of smoking is increasingly acknowledged but still insufficiently studied during the key period of student life. In particular, the simultaneous action of stress and Attention Deficit Hyperactivity Disorder (ADHD) symptoms on the risk of smoking remains poorly understood. AIMS To assess the effects of stress and ADHD symptoms on tobacco smoking. METHOD Multivariate modeling was conducted on the French i-Share study (n=8110, median age 20.3 years, 74.8% females, 32.9% regular/occasional smokers) to evaluate the associations between stress, ADHD symptoms and tobacco smoking, adjusting for potential family/socio-demographic confounders. RESULTS Students with high levels of stress were more likely to smoke>10 cigarettes/day (adjusted odds ratio (aOR): 1.48, 95% CI: 1.12-1.96) than those with low levels of stress. Students with high levels of ADHD symptoms were more likely to smoke>10 cigarettes/day (aOR: 2.08, 95% CI: 1.58-2.75) than those with low levels of ADHD symptoms. CONCLUSIONS Stress and ADHD contribute independently to the risk of smoking. Interventions targeting each condition are likely to reduce the burden of tobacco use in students.
Collapse
Affiliation(s)
- C Galéra
- UMR1219, université de Bordeaux, 33000 Bordeaux, France; UMR1219, Inserm, HEALTHY Team, 33000 Bordeaux, France; Centre hospitalier Perrens, 33076 Bordeaux, France.
| | - J Salla
- UMR1219, université de Bordeaux, 33000 Bordeaux, France; UMR1219, Inserm, HEALTHY Team, 33000 Bordeaux, France
| | - I Montagni
- UMR1219, université de Bordeaux, 33000 Bordeaux, France; UMR1219, Inserm, HEALTHY Team, 33000 Bordeaux, France
| | - S Hanne-Poujade
- UMR1219, université de Bordeaux, 33000 Bordeaux, France; UMR1219, Inserm, HEALTHY Team, 33000 Bordeaux, France
| | - R Salamon
- UMR1219, université de Bordeaux, 33000 Bordeaux, France; UMR1219, Inserm, HEALTHY Team, 33000 Bordeaux, France
| | - O Grondin
- UMR1219, université de Bordeaux, 33000 Bordeaux, France; UMR1219, Inserm, HEALTHY Team, 33000 Bordeaux, France
| | - E Guichard
- Inserm CIC1415, CHRU de Tours, 37044 Tours, France
| | - M P Bouvard
- UMR1219, université de Bordeaux, 33000 Bordeaux, France; Centre hospitalier Perrens, 33076 Bordeaux, France
| | - C Tzourio
- UMR1219, université de Bordeaux, 33000 Bordeaux, France; UMR1219, Inserm, HEALTHY Team, 33000 Bordeaux, France
| | - G Michel
- UMR1219, université de Bordeaux, 33000 Bordeaux, France; UMR1219, Inserm, HEALTHY Team, 33000 Bordeaux, France
| |
Collapse
|
43
|
Page KM, Labopin M, Ruggeri A, Michel G, Diaz de Heredia C, O'Brien T, Picardi A, Ayas M, Bittencourt H, Vora AJ, Troy J, Bonfim C, Volt F, Gluckman E, Bader P, Kurtzberg J, Rocha V. Factors Associated with Long-Term Risk of Relapse after Unrelated Cord Blood Transplantation in Children with Acute Lymphoblastic Leukemia in Remission. Biol Blood Marrow Transplant 2017; 23:1350-1358. [PMID: 28438676 PMCID: PMC5569913 DOI: 10.1016/j.bbmt.2017.04.015] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2017] [Accepted: 04/16/2017] [Indexed: 12/20/2022]
Abstract
For pediatric patients with acute lymphoblastic leukemia (ALL), relapse is an important cause of treatment failure after unrelated cord blood transplant (UCBT). Compared with other donor sources, relapse is similar or even reduced after UCBT despite less graft-versus-host disease (GVHD). We performed a retrospective analysis to identify risk factors associated with the 5-year cumulative incidence of relapse after UCBT. In this retrospective, registry-based study, we examined the outcomes of 640 children (<18 years) with ALL in first complete remission (CR1; n = 257, 40%) or second complete remission (CR2; n = 383, 60%) who received myeloablative conditioning followed by a single-unit UCBT from 2000 to 2012. Most received antithymocyte globulin (88%) or total body irradiation (TBI; 69%), and cord blood grafts were primarily mismatched at 1 (50%) or 2+ (34%) HLA loci. Considering patients in CR1, the rates of 5-year overall survival (OS), leukemia-free survival (LFS), and relapse were 59%, 52%, and 23%, respectively. In multivariate analysis (MVA), acute GVHD (grades II to IV) and TBI protected against relapse. In patients in CR2, rates of 5-year OS, LFS, and the cumulative incidence of relapse were 46%, 44%, and 28%, respectively. In MVA, longer duration from diagnosis to UCBT (≥30 months) and TBI were associated with decreased relapse risk. Importantly, receiving a fully HLA matched graft was a strong risk factor for increased relapse in MVA. An exploratory analysis of all 640 patients supported the important association between the presence of acute GVHD and less relapse but also demonstrated an increased risk of nonrelapse mortality. In conclusion, the impact of GVHD as a graft-versus-leukemia marker is evident in pediatric ALL after UCBT. Strategies that promote graft-versus-leukemia while harnessing GVHD should be further investigated.
Collapse
Affiliation(s)
- Kristin M Page
- Division of Pediatric Blood and Marrow Transplantation, Duke University Medical Center, Durham, North Carolina.
| | - Myriam Labopin
- EBMT, Acute Leukemia Working Party, Service d'hematologie et therapie cellulaire, Hôpital Saint Antoine, Paris, France
| | - Annalisa Ruggeri
- EBMT, Acute Leukemia Working Party, Service d'hematologie et therapie cellulaire, Hôpital Saint Antoine, Paris, France; Eurocord, Hospital Saint Louis APHP, University Paris-Diderot, Paris, France; Monacord, Centre Scientifique de Monaco, Monaco-Ville, Monaco
| | - Gerard Michel
- Timone Enfants Hospital and Aix-Marseille University, Department of Pediatric Hematology and Oncology, Marseille, France
| | | | - Tracey O'Brien
- Blood and Marrow Transplant Program, Sydney Children's Hospital, Randwick, New South Wales, Australia
| | | | - Mouhab Ayas
- Department of Pediatric Hematology/Oncology, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia
| | | | - Ajay J Vora
- Department of Pediatric Haematology, The Children's Hospital, Sheffield, UK; Department of Haematology and Oncology, Great Ormond Street Hospital, London, UK
| | - Jesse Troy
- Division of Pediatric Blood and Marrow Transplantation, Duke University Medical Center, Durham, North Carolina
| | - Carmen Bonfim
- Hospital Das Clinicas, Universidade Federal do Parana, Curitiba, Brazil
| | - Fernanda Volt
- Eurocord, Hospital Saint Louis APHP, University Paris-Diderot, Paris, France; Monacord, Centre Scientifique de Monaco, Monaco-Ville, Monaco
| | - Eliane Gluckman
- Eurocord, Hospital Saint Louis APHP, University Paris-Diderot, Paris, France; Monacord, Centre Scientifique de Monaco, Monaco-Ville, Monaco
| | - Peter Bader
- Division for Stem Cell Transplantation and Immunology, Hospital for Children and Adolescents, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany
| | - Joanne Kurtzberg
- Division of Pediatric Blood and Marrow Transplantation, Duke University Medical Center, Durham, North Carolina
| | - Vanderson Rocha
- Eurocord, Hospital Saint Louis APHP, University Paris-Diderot, Paris, France; Monacord, Centre Scientifique de Monaco, Monaco-Ville, Monaco; Hospital Das Clinicas, University of Sao Paulo, Sao Paulo, Brazil; Churchill Hospital, Oxford University, Oxford, UK
| |
Collapse
|
44
|
Shouval R, Ruggeri A, Labopin M, Mohty M, Sanz G, Michel G, Kuball J, Chevallier P, Al-Seraihy A, Milpied NJ, de Heredia CD, Arcese W, Blaise D, Rocha V, Fein J, Unger R, Baron F, Bader P, Gluckman E, Nagler A. An Integrative Scoring System for Survival Prediction Following Umbilical Cord Blood Transplantation in Acute Leukemia. Clin Cancer Res 2017; 23:6478-6486. [PMID: 28754820 DOI: 10.1158/1078-0432.ccr-17-0489] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2017] [Revised: 05/25/2017] [Accepted: 07/20/2017] [Indexed: 11/16/2022]
Abstract
Purpose: Survival of acute leukemia (AL) patients following umbilical cord blood transplantation (UCBT) is dependent on an array of individual features. Integrative models for risk assessment are lacking. We sought to develop a scoring system for prediction of overall survival (OS) and leukemia-free survival (LFS) at 2 years following UCBT in AL patients.Experimental Design: The study cohort included 3,140 pediatric and adult AL UCBT patients from the European Society of Blood and Marrow Transplantation and Eurocord registries. Patients received single or double cord blood units. The dataset was geographically split into a derivation (n = 2,362, 65%) and validation set (n = 778, 35%). Top predictors of OS were identified using the Random Survival Forest algorithm and introduced into a Cox regression model, which served for the construction of the UCBT risk score.Results: The score includes nine variables: disease status, diagnosis, cell dose, age, center experience, cytomegalovirus serostatus, degree of HLA mismatch, previous autograft, and anti-thymocyte globulin administration. Over the validation set an increasing score was associated with decreasing probabilities for 2 years OS and LFS, ranging from 70.21% [68.89-70.71, 95% confidence interval (CI)] and 64.76% (64.33-65.86, 95% CI) to 14.78% (10.91-17.41) and 18.11% (14.40-22.30), respectively. It stratified patients into six distinct risk groups. The score's discrimination (AUC) over multiple imputations of the validation set was 68.76 (68.19-69.04, range) and 65.78 (65.20-66.28) for 2 years OS and LFS, respectively.Conclusions: The UCBT score is a simple tool for risk stratification of AL patients undergoing UCBT. Widespread application of the score will require further independent validation. Clin Cancer Res; 23(21); 6478-86. ©2017 AACR.
Collapse
Affiliation(s)
- Roni Shouval
- Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-HaShomer, Ramat-Gan, Israel. .,Dr. Pinchas Bornstein Talpiot Medical Leadership Program, Chaim Sheba Medical Center, Tel-HaShomer, Ramat-Gan, Israel.,Sackler Faculty of Medicine, Tel-Aviv University, Israel.,Bar-Ilan University, Ramat Gan, Israel
| | - Annalisa Ruggeri
- Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint-Antoine, Paris, France.,Eurocord, Hospital Saint Louis, Paris, France
| | - Myriam Labopin
- Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint-Antoine, Paris, France.,Acute Leukemia Working Party EBMT Paris Office, Hôpital Saint-Antoine, Paris, France
| | - Mohamad Mohty
- Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint-Antoine, Paris, France.,Universite Pierre et Marie Curie, Paris, France
| | | | - Gerard Michel
- Timone Enfants Hospital and Aix-Marseille University, Marseille, France
| | - Jürgen Kuball
- University Medical Centre Utrecht, Utrecht, the Netherlands
| | | | - Amal Al-Seraihy
- King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia
| | | | | | | | | | - Vanderson Rocha
- Eurocord, Hospital Saint Louis, Paris, France.,Churchill Hospital, Oxford, United Kingdom
| | - Joshua Fein
- Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-HaShomer, Ramat-Gan, Israel.,Sackler Faculty of Medicine, Tel-Aviv University, Israel
| | - Ron Unger
- Bar-Ilan University, Ramat Gan, Israel
| | | | - Peter Bader
- Pediatric Diseases Working Party of the EBMT, Barcelona, Spain.,University Hospital Frankfurt, Frankfurt, Germany
| | - Eliane Gluckman
- Eurocord, Hospital Saint Louis, Paris, France.,Monacord, Centre Scientifique de Monaco, Monaco, France
| | - Arnon Nagler
- Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-HaShomer, Ramat-Gan, Israel.,Sackler Faculty of Medicine, Tel-Aviv University, Israel.,Acute Leukemia Working Party EBMT Paris Office, Hôpital Saint-Antoine, Paris, France.,Universite Pierre et Marie Curie, Paris, France
| |
Collapse
|
45
|
Jennings DE, Flasar FM, Kunde VG, Nixon CA, Segura ME, Romani PN, Gorius N, Albright S, Brasunas JC, Carlson RC, Mamoutkine AA, Guandique E, Kaelberer MS, Aslam S, Achterberg RK, Bjoraker GL, Anderson CM, Cottini V, Pearl JC, Smith MD, Hesman BE, Barney RD, Calcutt S, Vellacott TJ, Spilker LJ, Edgington SG, Brooks SM, Ade P, Schinder PJ, Coustenis A, Courtin R, Michel G, Fettig R, Pilorz S, Ferrari C. Composite infrared spectrometer (CIRS) on Cassini: publisher's note. Appl Opt 2017; 56:5897. [PMID: 29047908 DOI: 10.1364/ao.56.005897] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/29/2017] [Indexed: 06/07/2023]
Abstract
This publisher's note renumbers the reference list in Appl. Opt.56, 5274 (2017)APOPAI0003-693510.1364/AO.56.005274.
Collapse
|
46
|
Nguyen S, Achour A, Souchet L, Vigouroux S, Chevallier P, Furst S, Sirvent A, Bay JO, Socié G, Ceballos P, Huynh A, Cornillon J, Francois S, Legrand F, Yakoub-Agha I, Michel G, Maillard N, Margueritte G, Maury S, Uzunov M, Bulabois CE, Michallet M, Clement L, Dauriac C, Bilger K, Lejeune J, Béziat V, Rocha V, Rio B, Chevret S, Vieillard V. Clinical impact of NK-cell reconstitution after reduced intensity conditioned unrelated cord blood transplantation in patients with acute myeloid leukemia: analysis of a prospective phase II multicenter trial on behalf of the Société Française de Greffe de Moelle Osseuse et Thérapie Cellulaire and Eurocord. Bone Marrow Transplant 2017. [PMID: 28650455 DOI: 10.1038/bmt.2017.122] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Unrelated cord blood transplantation (UCBT) after a reduced intensity conditioning regimen (RIC) has extended the use of UCB in elderly patients and those with co-morbidities without an HLA-identical donor, although post-transplant relapse remains a concern in high-risk acute myeloid leukemia (AML) patients. HLA incompatibilities between donor and recipient might enhance the alloreactivity of natural killer (NK) cells after allogeneic hematopoietic stem-cell transplantation (HSCT). We studied the reconstitution of NK cells and KIR-L mismatch in 54 patients who underwent a RIC-UCBT for AML in CR in a prospective phase II clinical trial. After RIC-UCBT, NK cells displayed phenotypic features of both activation and immaturity. Restoration of their polyfunctional capacities depended on the timing of their acquisition of phenotypic markers of maturity. The incidence of treatment-related mortality (TRM) was correlated with low CD16 expression (P=0.043) and high HLA-DR expression (P=0.0008), whereas overall survival was associated with increased frequency of NK-cell degranulation (P=0.001). These features reflect a general impairment of the NK licensing process in HLA-mismatched HSCT and may aid the development of future strategies for selecting optimal UCB units and enhancing immune recovery.
Collapse
Affiliation(s)
- S Nguyen
- AP-HP, Hôpital Pitié Salpêtrière (AP-HP), Service d'Hématologie Clinique, Paris, France.,Sorbonne Universités, UPMC Univ Paris 06, INSERM U1135, CNRS ERL8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| | - A Achour
- Sorbonne Universités, UPMC Univ Paris 06, INSERM U1135, CNRS ERL8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| | - L Souchet
- AP-HP, Hôpital Pitié Salpêtrière (AP-HP), Service d'Hématologie Clinique, Paris, France
| | - S Vigouroux
- CHU de Bordeaux Hôpital du Haut-Lévèque, Service d'hématologie clinique et de thérapie cellulaire, Pessac, France
| | - P Chevallier
- CHU de Nantes, Hematology Department, Nantes, France
| | - S Furst
- Institut Paoli Calmettes, Service de greffe de moelle, Marseille, France
| | - A Sirvent
- Centre Hospitalier Universitaire de Montpellier, Montpellier, France
| | - J-O Bay
- CHU Estaing Service d'Hématologie Clinique, Clermont-Ferrand, France
| | - G Socié
- AP-HP, Hôpital Saint-Louis, Service d'Hématologie et de Transplantation, Paris, France
| | | | - A Huynh
- CHU de Toulouse, Hématologie Clinique, Toulouse, France
| | - J Cornillon
- Institut de Cancérologie de la Loire, Service d'Hématologie, Saint-Priest-en-Jarez, France
| | | | - F Legrand
- CHU de Nice, Service d'Hématologie, Nice, France
| | | | - G Michel
- Department of Pediatric Hematology and Oncology, Timone Enfants Hospital and Research Unit EA 3279 Aix-Marseille University, Marseille, France
| | | | | | - S Maury
- Hôpital Henri Mondor, Service d'Hématologie, Créteil, France
| | - M Uzunov
- AP-HP, Hôpital Pitié Salpêtrière (AP-HP), Service d'Hématologie Clinique, Paris, France
| | | | | | - L Clement
- University Hospital de Bordeaux, Bordeaux, France
| | | | - K Bilger
- CHRU de Strasbourg, Strasbourg, France
| | - J Lejeune
- Department de Bioinformatique et Statistique Médicale, Hôpital Saint-Louis, Paris, France
| | - V Béziat
- Sorbonne Universités, UPMC Univ Paris 06, INSERM U1135, CNRS ERL8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| | - V Rocha
- Eurocord Office, Hôpital Saint-Louis, Paris, France
| | - B Rio
- Hôpital Saint-Antoine, Hématologie Clinique et Thérapie Cellulaire, Paris, France
| | - S Chevret
- Department de Bioinformatique et Statistique Médicale, Hôpital Saint-Louis, Paris, France
| | - V Vieillard
- Sorbonne Universités, UPMC Univ Paris 06, INSERM U1135, CNRS ERL8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| |
Collapse
|
47
|
Jennings DE, Flasar FM, Kunde VG, Nixon CA, Segura ME, Romani PN, Gorius N, Albright S, Brasunas JC, Carlson RC, Mamoutkine AA, Guandique E, Kaelberer MS, Aslam S, Achterberg RK, Bjoraker GL, Anderson CM, Cottini V, Pearl JC, Smith MD, Hesman BE, Barney RD, Calcutt S, Vellacott TJ, Spilker LJ, Edgington SG, Brooks SM, Ade P, Schinder PJ, Coustenis A, Courtin R, Michel G, Fettig R, Pilorz S, Ferrari C. Composite infrared spectrometer (CIRS) on Cassini. Appl Opt 2017; 56:5274-5294. [PMID: 29047582 DOI: 10.1364/ao.56.005274] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/12/2017] [Accepted: 05/25/2017] [Indexed: 06/07/2023]
Abstract
The Cassini spacecraft orbiting Saturn carries the composite infrared spectrometer (CIRS) designed to study thermal emission from Saturn and its rings and moons. CIRS, a Fourier transform spectrometer, is an indispensable part of the payload providing unique measurements and important synergies with the other instruments. It takes full advantage of Cassini's 13-year-long mission and surpasses the capabilities of previous spectrometers on Voyager 1 and 2. The instrument, consisting of two interferometers sharing a telescope and a scan mechanism, covers over a factor of 100 in wavelength in the mid and far infrared. It is used to study temperature, composition, structure, and dynamics of the atmospheres of Jupiter, Saturn, and Titan, the rings of Saturn, and surfaces of the icy moons. CIRS has returned a large volume of scientific results, the culmination of over 30 years of instrument development, operation, data calibration, and analysis. As Cassini and CIRS reach the end of their mission in 2017, we expect that archived spectra will be used by scientists for many years to come.
Collapse
|
48
|
Eapen M, Wang T, Veys PA, Boelens JJ, St Martin A, Spellman S, Bonfim CS, Brady C, Cant AJ, Dalle JH, Davies SM, Freeman J, Hsu KC, Fleischhauer K, Kenzey C, Kurtzberg J, Michel G, Orchard PJ, Paviglianiti A, Rocha V, Veneris MR, Volt F, Wynn R, Lee SJ, Horowitz MM, Gluckman E, Ruggeri A. Allele-level HLA matching for umbilical cord blood transplantation for non-malignant diseases in children: a retrospective analysis. Lancet Haematol 2017. [PMID: 28623181 DOI: 10.1016/s2352-3026(17)30104-7] [Citation(s) in RCA: 60] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
BACKGROUND The standard for selecting unrelated umbilical cord blood units for transplantation for non-malignant diseases relies on antigen-level (lower resolution) HLA typing for HLA-A and HLA-B, and allele-level for HLA-DRB1. We aimed to study the effects of allele-level matching at a higher resolution-HLA-A, HLA-B, HLA-C, and HLA-DRB1, which is the standard used for adult unrelated volunteer donor transplantation for non-malignant diseases-for umbilical cord blood transplantation. METHODS We retrospectively studied 1199 paediatric donor-recipient pairs with allele-level HLA matching who received a single unit umbilical cord blood transplantation for non-malignant diseases reported to the Center for International Blood and Marrow Transplant Research or Eurocord and European Group for Blood and Marrow Transplant. Transplantations occurred between Jan 1, 2000, and Dec 31, 2012. The primary outcome was overall survival. The effect of HLA matching on survival was studied using a Cox regression model. FINDINGS Compared with HLA-matched transplantations, mortality was higher with transplantations mismatched at two (hazard ratio [HR] 1·55, 95% CI 1·08-2·21, p=0·018), three (2·04, 1·44-2·89, p=0·0001), and four or more alleles (3·15, 2·16-4·58, p<0·0001). There were no significant differences in mortality between transplantations that were matched and mismatched at one allele (HR 1·18, 95% CI 0·80-1·72, p=0·39). Other factors associated with higher mortality included recipient cytomegalovirus seropositivity (HR 1·40, 95% CI 1·13-1·74, p=0·0020), reduced intensity compared with myeloablative conditioning regimens (HR 1·36, 1·10-1·68, p=0·0041), transplantation of units with total nucleated cell dose of more than 21 × 107 cells per kg compared with 21 × 107 cells per kg or less (HR 1·47, 1·11-1·95, p=0·0076), and transplantations done in 2000-05 compared with those done in 2006-12 (HR 1·64, 1·31-2·04, p<0·0001). The 5-year overall survival adjusted for recipient cytomegalovirus serostatus, conditioning regimen intensity, total nucleated cell dose, and transplantation period was 79% (95% CI 74-85) after HLA matched, 76% (71-81) after one allele mismatched, 70% (65-75) after two alleles mismatched, 62% (57-68) after three alleles mismatched, and 49% (41-57) after four or more alleles mismatched transplantations. Graft failure was the predominant cause of mortality. INTERPRETATION These data support a change from current practice in that selection of unrelated umbilical cord blood units for transplantation for non-malignant diseases should consider allele-level HLA matching at HLA-A, HLA-B, HLA-C, and HLA-DRB1. FUNDING National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute for Allergy and Infectious Diseases; US Department of Health and Human Services-Health Resources and Services Administration; and US Department of Navy.
Collapse
Affiliation(s)
- Mary Eapen
- Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
| | - Tao Wang
- Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA
| | - Paul A Veys
- Bone Marrow Transplantation Department, Great Ormond Street Hospital, London, UK
| | - Jaap J Boelens
- Paediatric Blood and Marrow Transplantation Program, University Medical Center Utrecht, Utrecht, Netherlands
| | - Andrew St Martin
- Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA
| | | | | | | | - Andrew J Cant
- Paediatric Immunology and Infection, Newcastle General Hospital, Newcastle-upon-Tyne, UK
| | - Jean-Hugues Dalle
- Paediatric Haematology Department, Hôpital Robert Debre, Paris, France
| | - Stella M Davies
- Department of Paediatrics, Cincinnati Children's Hospital, Cincinnati, OH, USA
| | - John Freeman
- National Marrow Donor Program, Minneapolis, MN, USA
| | - Katherine C Hsu
- Department of Medicine, Memorial Sloane Kettering Cancer Center, New York, NY, USA
| | | | | | | | - Gerard Michel
- Department of Paediatrics and Paediatric Haematology, University Hospital of Marseille, Marseille, France
| | - Paul J Orchard
- Department of Paediatrics, University of Minnesota, Minneapolis, MN, USA
| | | | - Vanderson Rocha
- Oxford Cancer and Haematology Center, Churchill Hospital, Oxford, UK
| | | | | | - Robert Wynn
- Pediatric Haematology, Central Manchester University Hospitals, Manchester, UK
| | - Stephanie J Lee
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Mary M Horowitz
- Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA
| | | | - Annalisa Ruggeri
- Service d'Haematologie et Therapie Cellulaire, Hôpital Saint Antoine, Paris, France
| |
Collapse
|
49
|
Plaum B, Gantenbein G, Kasparek W, Schwörer K, Grünert M, Braune H, Erckmann V, Hollmann F, Jonitz L, Laqua H, Michel G, Noke F, Purps F, Bruschi A, Cirant S, Gandini F, Verhoeven AGA. High-Power Tests of a Remote-Steering Antenna at 140 GHz. Fusion Science and Technology 2017. [DOI: 10.13182/fst06-a1216] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- B. Plaum
- Institut für Plasmaforschung, Universität Stuttgart, Pfaffenwaldring 31, D-70569 Stuttgart, Germany
| | - G. Gantenbein
- Institut für Plasmaforschung, Universität Stuttgart, Pfaffenwaldring 31, D-70569 Stuttgart, Germany
| | - W. Kasparek
- Institut für Plasmaforschung, Universität Stuttgart, Pfaffenwaldring 31, D-70569 Stuttgart, Germany
| | - K. Schwörer
- Institut für Plasmaforschung, Universität Stuttgart, Pfaffenwaldring 31, D-70569 Stuttgart, Germany
| | - M. Grünert
- Institut für Plasmaforschung, Universität Stuttgart, Pfaffenwaldring 31, D-70569 Stuttgart, Germany
| | - H. Braune
- Max-Planck-Institut für Plasmaphysik, EURATOM-Association, D-17491 Greifswald, Germany
| | - V. Erckmann
- Max-Planck-Institut für Plasmaphysik, EURATOM-Association, D-17491 Greifswald, Germany
| | - F. Hollmann
- Max-Planck-Institut für Plasmaphysik, EURATOM-Association, D-17491 Greifswald, Germany
| | - L. Jonitz
- Max-Planck-Institut für Plasmaphysik, EURATOM-Association, D-17491 Greifswald, Germany
| | - H. Laqua
- Max-Planck-Institut für Plasmaphysik, EURATOM-Association, D-17491 Greifswald, Germany
| | - G. Michel
- Max-Planck-Institut für Plasmaphysik, EURATOM-Association, D-17491 Greifswald, Germany
| | - F. Noke
- Max-Planck-Institut für Plasmaphysik, EURATOM-Association, D-17491 Greifswald, Germany
| | - F. Purps
- Max-Planck-Institut für Plasmaphysik, EURATOM-Association, D-17491 Greifswald, Germany
| | - A. Bruschi
- Instituto di Fisica del Plasma, EURATOM-ENEA-CNR Association, via R Cozzi 53, 20125 Milano, Italy
| | - S. Cirant
- Instituto di Fisica del Plasma, EURATOM-ENEA-CNR Association, via R Cozzi 53, 20125 Milano, Italy
| | - F. Gandini
- Instituto di Fisica del Plasma, EURATOM-ENEA-CNR Association, via R Cozzi 53, 20125 Milano, Italy
| | - A. G. A. Verhoeven
- FOM Institute for Plasma Physics Rijnhuizen, Association EURATOM-FOM, Nieuwegein, The Netherlands
| | | |
Collapse
|
50
|
Erckmann V, Kasparek W, Koshurinov Y, Lubyako L, Petelin MI, Shchegolkov DY, Hollmann F, Michel G, Noke F, Purps F. Power Combination of Two 140-GHz Gyrotrons and Fast Switching of the Combined Beam. Fusion Science and Technology 2017. [DOI: 10.13182/fst09-a4050] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- V. Erckmann
- Max-Planck-Institut für Plasmaphysik, EURATOM Association, Teilinstitut Greifswald, D-17491 Greifswald, Germany
| | - W. Kasparek
- Institut für Plasmaforschung, Universität Stuttgart, Pfaffenwaldring 31, D-70569 Stuttgart, Germany
| | - Y. Koshurinov
- Institute of Applied Physics, RAS, 603950 Nizhny Novgorod, Russia
| | - L. Lubyako
- Institute of Applied Physics, RAS, 603950 Nizhny Novgorod, Russia
| | - M. I. Petelin
- Institute of Applied Physics, RAS, 603950 Nizhny Novgorod, Russia
| | | | - F. Hollmann
- Max-Planck-Institut für Plasmaphysik, EURATOM Association, Teilinstitut Greifswald, D-17491 Greifswald, Germany
| | - G. Michel
- Max-Planck-Institut für Plasmaphysik, EURATOM Association, Teilinstitut Greifswald, D-17491 Greifswald, Germany
| | - F. Noke
- Max-Planck-Institut für Plasmaphysik, EURATOM Association, Teilinstitut Greifswald, D-17491 Greifswald, Germany
| | - F. Purps
- Max-Planck-Institut für Plasmaphysik, EURATOM Association, Teilinstitut Greifswald, D-17491 Greifswald, Germany
| | | | | | | | | | | |
Collapse
|